Document:

Execution
Copy

    

    EMPLOYMENT
AGREEMENT

     

    THIS EMPLOYMENT AGREEMENT (“Agreement”) is made
this 16th day of March, 2009 by and between NeoGenomics, Inc. a Nevada
corporation (“NeoGenomics" or the
“Employer” and
collectively with any entity that is wholly or partially owned by NeoGenomics,
the “Company”), located at 12701 Commonwealth Drive, Suite #5, Fort Myers,
Florida 33913 and Douglas M. VanOort (“Executive”), an
individual who resides at 3275 Regatta Road, Naples, FL 34103.

    

    RECITALS:

    

    WHEREAS, the Company is
engaged in the business of providing genetic and molecular diagnostic testing
services to doctors, hospitals and other healthcare institutions;
and

    

    WHEREAS, the Executive was
appointed to the Board of Directors of NeoGenomics (the “Board”) and elected as
the Chairman of the Board as of the date of this Agreement; and

    

    WHEREAS, NeoGenomics desires
to employ Executive as an officer in the capacity of Executive Chairman and
Interim Chief Executive Officer, and Executive desires to be employed by
NeoGenomics in such capacity, in accordance with the terms, covenants, and
conditions as set forth in this Agreement.

    

    NOW, THEREFORE, in
consideration of the mutual promises set forth herein and other good and
valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, the Employer and Executive agree as follows:

    

    1.           Employment
Period.  Subject to the terms and conditions set forth herein
and unless sooner terminated as hereinafter provided, NeoGenomics shall employ
Executive as an officer, and Executive agrees to serve as an officer and accepts
such employment for a four-year period, beginning on March 16, 2009 (the “Effective Date”) and
ending on the 4th
anniversary of the Effective Date (the “Initial Employment
Term”).  After the Initial Employment Term, this Agreement
shall automatically renew for consecutive one year periods (“renewal term”),
unless a written notice of a party’s intention to terminate this Agreement at
the expiration of the Initial Employment Term (or any renewal term) is delivered
by either party at least three (3) months prior to the expiration of the Initial
Employment Term or any renewal term, as applicable.  For purposes of
this Agreement, the period from the Effective Date until the termination of the
Executive’s employment shall hereinafter be referred to as the “Term”.  Executive’s
employment pursuant to this Agreement shall be “at will” as such term is
construed under Florida law.

    

    2.           Title and
Duties.  During the Term, NeoGenomics shall employ Executive in
the capacity of Executive Chairman.  In addition, during the period
from the Effective Date until the time that NeoGenomics hires a full-time Chief
Executive Officer (“CEO”), NeoGenomics
shall additionally employ Executive in the capacity of Interim CEO (such period
hereinafter referred to as the “CEO
Period”).  Executive accepts employment in these
capacities.  Executive will report to and be subject to the general
supervision and direction of the Board.  If requested, Executive will
serve in similar capacities for each or any subsidiary of NeoGenomics without
additional compensation.  Executive shall perform such duties as are
customarily performed by someone holding the title of Executive Chairman and/or
Interim CEO in the same or similar businesses or enterprises as that engaged in
by the Company and such other duties as the Board may assign from time to
time.

    

    3.           Compensation
and Benefits of Executive.  The Company shall compensate
Executive for Executive's services rendered under this Agreement as
follows:

    

    
      
        
          	 
      	
                  Executive Initials

                
	 
      	 
      
	 
      	 
      

        

      

    

     

    
      
         

      

      
        1

        
          

        

      

      
         

      

    

    
      	
               
      

            	
              a.

            	
              Base
      Salary.  Unless otherwise adjusted by the Compensation
      Committee of the Board (the “Compensation Committee”), the Company shall
      pay Executive a Core Base Salary and an Incremental CEO Base Salary (as
      such terms are defined below, and collectively referred to as the “Base Salary”),
      payable in equal installments at such times as is consistent with normal
      Company payroll policy, according to the following
  amounts:

            

    

    

    
      	
               
      

            	
              1.)  A
      base salary equating to two hundred twenty five thousand dollars
      ($225,000) per annum (the “Core Base
      Salary”) until the end of the Term or until such time that the
      Executive desires to reduce his work time commitment to the Company to
      less than 2.5 days per week, in which case the Board and Executive will
      work in good faith to determine a new Core Base Salary that is
      appropriate.

            

    

    

    
      	
               
      

            	
              2.)  During
      the CEO Period and so long as Executive is able to spend at least one (1)
      additional day per week on average on the Company’s affairs (for a total
      of 3.5 days/week on average), the Company agrees to pay an additional
      amount in base salary (the “Incremental CEO Base
      Salary”) equal to $50,000 per annum.  In the event that
      the Executive is unable to dedicate a least 3.5 days/week on average on
      the affairs of the Company, the Board and the Executive agree to work in
      good faith to determine a new Incremental CEO Base Salary that is
      appropriate.

            

    

    

    
      	
               
      

            	
              b.

            	
              Bonus.  Executive
      will be eligible for an annual cash bonus based on
      performance.  The amount of such bonus shall be based on the
      available resources of the Company and shall be at the discretion of the
      Compensation Committee; provided, however, if the Company’s actual
      performance in any given fiscal year meets or exceeds the below listed
      annual performance goals for such fiscal year, the Executive shall be
      entitled to the cash bonuses outlined below for such fiscal
      year.  The Company agrees that such cash bonus, if any, will be
      paid no later than ninety (90) days after the end of the fiscal year to
      which it applied.

            

    

    

    
      	
               
      

            	
              1.)  For
      any given fiscal year during the Term, if the Company’s actual
      consolidated revenue for such fiscal year, after excluding the effects of
      any Revenue Exclusions (as defined in Section 3e(1) below), exceeds the
      annual revenue goals approved by the Board for such fiscal year based on
      the Board-approved Company budget for such year, Executive shall be
      entitled to a cash bonus of at least fifteen percent (15%) of his Base
      Salary as such Base Salary was in effect as of the end of such fiscal
      year; and

            

    

    

    
      	
               
      

            	
              2.)  For
      any given fiscal year during the Term, if the Company’s actual Adjusted
      EBITDA (as defined below) after excluding the effects of any Adjusted
      EBITDA Exclusions (as defined in Section 3e(2) below), exceeds the annual
      goals for Adjusted EBITDA approved by the Board for such fiscal year based
      on the Board-approved Company budget for such year, Executive shall be
      entitled to a cash bonus of at least fifteen percent (15%) of his Base
      Salary as such Base Salary was in effect as of the end of such fiscal
      year.  For the purposes of this Agreement, “Adjusted
      EBITDA” is defined as consolidated GAAP earnings before interest,
      taxes, depreciation, amortization, and non-cash stock based compensation
      expenses.  In addition, any extraordinary or non-recurring
      actual expenses incurred by the Company that were not included in the
      budget for the applicable fiscal year that in the reasonable judgment of
      the Compensation Committee could not have been foreseen by the Company’s
      management during the process to set the budget for such year may, at the
      Board’s discretion, also be added back to the total when calculating
      actual Adjusted EBITDA for such fiscal
year.

            

    

     

    
      
        
          
            	 
      	
                    Executive Initials

                  
	 
      	 
      
	 
      	 
      

          

        

      

       

    

    
      
         

      

      
        2

        
          

        

      

      
         

      

    

     

    
      	
               
      

            	
              c.

            	
              Benefits.  Subject
      to the eligibility requirements (including, but not limited to,
      participation by part-time employees), and enrollment provisions of the
      Company’s employee benefit plans, Executive may, to the extent he so
      chooses, participate in any and all of the Company’s employee benefit
      plans, at the Company’s expense.  All Company benefits are
      identified in the Employee Handbook and are subject to change without
      notice or explanation.  In addition, subject to the eligibility
      requirements (including, but not limited to, participation by a part-time
      employee) and enrollment provisions of the Company’s executive benefit
      programs, Executive shall also be entitled to participate in any and all
      other benefits programs established for officers of the
      Company.

            

    

    

    
      	
               
      

            	
              d.

            	
              Stock
      Options.  On the Effective Date, Executive will be
      granted an option to purchase 1,000,000 shares of the Company’s common
      stock (the “Options”) on
      the terms and conditions listed below.  Such Options will have a
      strike price equal to the fair market value of the common stock as of the
      Effective Date, which pursuant to NeoGenomics’ Amended and Restated Equity
      Incentive Plan (the “Plan”), shall be equal to the closing price per share
      of NeoGenomics’ common stock on the last trading day immediately preceding
      the Effective Date.  The vesting provisions of such Options
      shall be as outlined below.  These Options shall be treated as
      incentive stock options (ISOs) to the maximum extent permitted under
      applicable law, and the remainder of the Options, if any, shall be treated
      as non-qualified stock options.  The grant of these Options will
      be made pursuant to the Company’s Plan and will be evidenced by a separate
      “Option
      Agreement” to be executed by the Company and Executive, which will
      contain all the terms and conditions of the Options (including, but not
      limited to, the provisions set forth in this Section 3(d)).  So
      long as Executive remains employed by the Company, such Options will have
      a seven-year term before
expiration.

            

    

    

    
      1.)       Time-based
Options - 500,000 of such options will be time-based options and will
vest according to the following schedule:

    

    

    
      	
               
      

            	
              200,000

            	
              will
      vest on the first anniversary of the Effective Date; provided, however,
      that if the Executive’s employment hereunder is terminated by the Employer
      without “cause” (as such term is defined in the Option Agreement) at any
      time prior to the first anniversary of the Effective Date, then the pro
      rata portion of these 200,000 Options up until the date of termination,
      shall be deemed vested; and

            

    

     

    
      	
               
      

            	
              12,500

            	
              will
      vest each month beginning on the 13th
      monthly anniversary of the Effective Date and continuing on each monthly
      anniversary thereafter until the second anniversary of the Effective Date;
      and

            

    

     

    
      	
               
      

            	
              8,000

            	
              will
      vest each month beginning on the 25th
      monthly anniversary of the Effective Date and continuing on each monthly
      anniversary thereafter until the third anniversary of the Effective Date;
      and

            

    

     

    
      	
               
      

            	
              4,500

            	
              will
      vest each month beginning on the 37th
      monthly anniversary of the Effective Date and continuing on each monthly
      anniversary thereafter until the fourth anniversary of the Effective
      Date.

            

    

    

    
      2.)     
 Performance-based
Options - 500,000 of such options will be performance-based options and
will vest according to the following schedule.  Executive understands
and acknowledges that if the performance metrics for any given year are not met,
then such options shall be forfeited and the Board is under no obligation to
replenish such options.

    

     

    
      
        
          
            	 
      	
                    Executive Initials

                  
	 
      	 
      
	 
      	 
      

          

        

      

       

    

    
      
         

      

      
        3

        
          

        

      

      
         

      

    

    
      	
               
      

            	
              100,000

            	
              will
      vest if the Company’s actual consolidated revenue for FY 2009, after
      excluding the effects of any Revenue Exclusions for such fiscal year,
      meets or exceeds the consolidated revenue goal established by the Board
      for the vesting of performance options, which goal will be based on the
      Company’s Board approved budget for such fiscal year;
  and

            

    

     

    
      	
               
      

            	
              100,000

            	
              will
      vest if the Company’s actual Adjusted EBITDA for FY 2009, after excluding
      the effects of any Adjusted EBITDA Exclusions for such fiscal year, meets
      or exceeds the Adjusted EBITDA goal established by the Board for the
      vesting of performance options, which will be based on the Company’s
      Board-approved budget for such fiscal year;
and

            

    

     

    
      	
               
      

            	
              75,000

            	
              will
      vest if the Company’s actual consolidated revenue for FY 2010, after
      excluding the effects of any Revenue Exclusions for such fiscal year,
      meets or exceeds the consolidated revenue goal established by the Board
      for the vesting of performance options, which goal will be based on the
      Company’s Board approved budget for such fiscal year;
  and

            

    

     

    
      	
               
      

            	
              75,000

            	
              will
      vest if the Company’s actual Adjusted EBITDA for FY 2010, after excluding
      the effects of any Adjusted EBITDA Exclusions for such fiscal year, meets
      or exceeds the Adjusted EBITDA goal established by the Board for the
      vesting of performance options, which will be based on the Company’s
      Board-approved budget for such fiscal year;
and

            

    

     

    
      	
               
      

            	
              50,000

            	
              will
      vest if the Company’s actual consolidated revenue for FY 2011, after
      excluding the effects of any Revenue Exclusions for such fiscal year,
      meets or exceeds the consolidated revenue goal established by the Board
      for the vesting of performance options, which goal will be based on the
      Company’s Board approved budget for such fiscal year;
  and

            

    

     

    
      	
               
      

            	
              50,000

            	
              will
      vest if the Company’s actual Adjusted EBITDA for FY 2011, after excluding
      the effects of any Adjusted EBITDA Exclusions for such fiscal year, meets
      or exceeds the Adjusted EBITDA goal established by the Board for the
      vesting of performance options, which will be based on the Company’s
      Board-approved budget for such fiscal year;
and

            

    

     

    
      	
               
      

            	
              25,000

            	
              will
      vest if the Company’s actual consolidated revenue for FY 2012, after
      excluding the effects of any Revenue Exclusions for such fiscal year,
      meets or exceeds the consolidated revenue goal established by the Board
      for the vesting of performance options, which goal will be based on the
      Company’s Board approved budget for such fiscal year;
  and

            

    

     

    
      	
               
      

            	
              25,000

            	
              will
      vest if the Company’s actual Adjusted EBITDA for FY 2012, after excluding
      the effects of any Adjusted EBITDA Exclusions for such fiscal year, meets
      or exceeds the Adjusted EBITDA goal established by the Board for the
      vesting of performance options, which will be based on the Company’s
      Board-approved budget for such fiscal
year.

            

    

     

    
      	
               
      

            	
              Executive
      understands that, pursuant to the Plan, upon termination of his
      employment, he will only have ninety (90) days to exercise any vested
      portion of the Options.  All Options awarded pursuant to this
      Section 3(d) will contain a provision in the Option Agreement that allows
      for immediate vesting of any unvested portion of the Options in the event
      of a change of control of
NeoGenomics.

            

    

     

    
      
        
          
            	 
      	
                    Executive Initials

                  
	 
      	 
      
	 
      	 
      

          

        

      

       

    

    
      
         

      

      
        4

        
          

        

      

      
         

      

    

    
      	
               
      

            	
              e.

            	
              Revenue
      and Adjusted EBITDA Exclusions Defined.  For the purposes
      of Section 3b and 3d above, to the extent the Company acquires any
      companies or businesses during any given fiscal year and the financial
      impact of such acquisition was not previously factored into the annual
      operating budget approved by the Board, the following revenue and Adjusted
      EBITDA adjustments shall be made to the Company’s fiscal results in
      measuring whether or not the Company has met or exceeded the specific
      performance targets outlined in Sections  3b or 3d
      hereof.

            

    

    

    
      	
               
      

            	
              1.)  “Revenue
      Exclusions” shall be defined as the prorated annualized quarterly
      GAAP revenue of any company or business acquired by the Company for the
      most recent full fiscal quarter prior to the date such company or business
      is acquired by the Company.  Such annualized quarterly revenue
      shall be prorated by multiplying the total annualized quarterly revenue
      described above by a fraction, the numerator of which is the number of
      days that the financial results of the acquired business or company are
      included in the Company’s financial results during the fiscal year in
      question, and the denominator of which is
365.

            

    

    

    
      	
               
      

            	
              2.)  “Adjusted EBITDA
      Exclusions” shall be defined as the prorated annualized quarterly
      Adjusted EBITDA of any company or business acquired by the Company for the
      most recent full fiscal quarter prior to the date such company or business
      is acquired by the Company.  Such annualized quarterly Adjusted
      EBITDA shall be prorated by multiplying the total annualized quarterly
      Adjusted EBITDA described above by a fraction, the numerator of which is
      the number of days that the financial results of the acquired business or
      company are included in the Company’s financial results during the fiscal
      year in question, and the denominator of which is 365.  The
      Board, at its discretion, may add back any non-recurring or one time
      charges that may have been included in the most recent full fiscal quarter
      of the company or business being acquired when determining the appropriate
      Adjusted EBITDA for such business or
company.

            

    

    

    
      	
               
      

            	
              f.

            	
              Paid
      Time-Off and Holidays.  Executive’s paid time-off (“PTO”) and
      holidays shall be consistent with the standards set forth in the Company’s
      Employee Handbook, as revised from time to time or as otherwise published
      by the Company.  Notwithstanding the previous sentence,
      Executive will be eligible for one hundred twenty (120) hours of PTO/year,
      which will accrue on a pro-rata basis throughout the year, provided,
      however, that it is the Company’s policy that no more than forty (40)
      hours of PTO can be accrued beyond this annual limit for any employee at
      any time.  Thus, when accrued PTO reaches one hundred sixty
      (160) hours, Executive will cease accruing PTO until accrued PTO is one
      hundred twenty (120) hours or less, at which point Executive will again
      accrue PTO until he reaches one hundred sixty (160) hours.  In
      addition to PTO, there are also six (6) paid national holidays and one (1)
      “floater” day available to Company employees.  Executive agrees
      to schedule such PTO so that it minimally interferes with the Company’s
      operations.   Such PTO does not include Board excused
      absences.

            

    

    

    
      	
               
      

            	
              g.

            	
              Reimbursement
      of Normal Business Expenses.  The Company will reimburse
      all reasonable business expenses of Executive, including, but not limited
      to, cell phone expenses and business related travel, meals and
      entertainment expenses in accordance with the Company’s polices for such
      reimbursement.

            

    

    

    4.           Best
Efforts of the Executive and Minimum Time Commitments of Employment. Executive agrees to
perform all of the duties pursuant to the express and implicit terms of this
Agreement to the reasonable satisfaction of the Employer.  Executive
further agrees to perform such duties faithfully and to the best of his ability,
talent, and experience and, unless otherwise agreed to with the Company in
writing, to render such duties at least in the minimum amounts of time specified
below:

     

    
      
        
          
            	 
      	
                    Executive Initials

                  
	 
      	 
      
	 
      	 
      

          

           

          
            
              
                 

              

              
                5

                
                  

                

              

              
                 

              

            

          

          

        

      

    

    
      	
               
      

            	
              a.

            	
              So
      long as the Executive and the Board have not agreed to adjust downward the
      Executive’s Core Base Salary specified in Section 3(a), Executive agrees
      that during the Term, except for those weeks where he is on PTO, he will
      spend at least two and one-half (2.5) days/week on average on the
      Company’s business (such period as may be adjusted, the “Minimum Weekly Time
      Commitment”).   Executive further agrees that he
      will use commercially reasonable efforts to ensure that except for those
      weeks where he is on PTO, he will work at least two (2) days on average
      either at the Company’s primary place of business in Fort Myers, FL or at
      such other place or places as the interests, needs, business, or
      opportunities of the Employer shall require and/or such other place as may
      be mutually agreed upon in writing by the parties (such period as may be
      adjusted, the “On-Site/Business
      Travel Time Commitment”).

            

    

    

    
      	
               
      

            	
              b.

            	
              Notwithstanding
      the forgoing, Executives agrees that during the CEO Period, the Minimum
      Weekly Time Commitment shall be increased to three and one-half (3.5) days
      and the On-Site/Business Travel Time Commitment shall be increased to
      three (3) days.

            

    

    

    5.           Termination.  Either
party may terminate Executive’s employment with the Company at any time upon
giving sixty (60) days advance written notice to the other party. Executive
agrees that in order to help facilitate an orderly transition of authority,
unless otherwise agreed to by the parties, during such sixty (60) day notice
period no more than two weeks of unused PTO may be utilized.   In
the event of the death of Executive, the employment of Executive shall
automatically terminate on the date of Executive's death.  Within 30
days following the date Executive’s employment terminates, the Company shall pay
to Executive (or Executive’s estate if applicable) (a) the Executive’s accrued
but unpaid Base Salary through the date of termination, (b) any bonus earned by,
but not yet paid to, Executive from the prior fiscal year, (c) an amount equal
to the reasonable business expenses incurred by Executive (in accordance with
Company policy), but not yet reimbursed, prior to the termination date, and (d)
other benefits due and owing to Executive through the termination
date.

    

    6.           Confidentiality,
Non-Compete & Non-Solicitation Agreement.  Executive agrees
to the terms of the Confidentiality, Non-Solicitation and Non-Compete Agreement
attached hereto as Addendum A and has
signed that Agreement.  Such Confidentiality, Non-Solicitation and
Non-Compete Agreement is hereby incorporated into and made a part of this
Agreement.

    

    7.           Importance
of Certain Clauses.  Executive and Employer agree that the
covenants contained in the Confidentiality, Non-Solicitation and Non-Compete
Agreement attached hereto and incorporated into this Agreement are material
terms of this Agreement and all parties understand the importance of such
provisions to the ongoing business of the Employer.  As such, because
the Employer's continued business and viability depend on the protection of such
secrets and non-competition, these clauses are interpreted by the parties to
have the widest and most expansive applicability as may be allowed by law and
Executive understands and acknowledges his or her understanding of
same.

    

    8.           Consideration.  Executive
acknowledges and agrees that the provision of employment under this Agreement
and the execution by the Employer of this Agreement constitute full, adequate
and sufficient consideration to Executive for the Executive's duties,
obligations and covenants under this Agreement and under the Confidentiality,
Non-Solicitation and Non-Compete Agreement incorporated into this
Agreement.

     

    
      
        
          
            	 
      	
                    Executive Initials

                  
	 
      	 
      
	 
      	 
      

            
              
                 

              

              
                6

                
                  

                

              

              
                 

              

            

          

        

      

    

     

    9.           Acknowledgement
of Post Termination Obligations.  Upon the effective date of
termination of Executive’s employment (unless due to Executive’s death), if
requested by the Employer, Executive shall participate in an exit interview with
the Employer and certify in writing that Executive has complied with his
contractual obligations and intends to comply with his continuing obligations
under this Agreement, including, but not limited to, the terms of the
Confidentiality, Non-Solicitation and Non-Compete Agreement.  To the
extent it is known or applicable at the time of such exit interview, Executive
shall also provide the Employer with information concerning Executive's
subsequent employer and the capacity in which Executive will be employed.
Executive's failure to comply shall be a material breach of this Agreement, for
which the Employer, in addition to any other civil remedy, may seek equitable
relief.

    

    10.        Withholding.
All payments made to Executive shall be made net of any applicable withholding
for income taxes and Executive's share of FICA, FUTA or other employment taxes.
The Company shall withhold such amounts from such payments to the extent
required by applicable law and remit such amounts to the applicable governmental
authorities in accordance with applicable law.

    

    11.        Representations
of Executive.  Executive represents and warrants to NeoGenomics
that (a) nothing in his past legal and/or work and/or personal experiences,
which if became broadly known in the marketplace, would impair his ability to
serve as the Chief Executive Officer of a publicly-traded company or materially
damage his credibility with public shareholders; (b) there are no restrictions,
agreements, or understandings whatsoever to which he  is a party which
would prevent or make unlawful his execution of this Agreement or employment
hereunder, (c) Executive’s execution of this Agreement and employment hereunder
shall not constitute a breach of any contract, agreement or understanding, oral
or written, to which he is a party or by which he is bound, (d) Executive is
free and able to execute this Agreement and to continue  employment
with NeoGenomics, and (e) Executive has not used and will not use confidential
information or trade secrets belonging to any prior employers to perform
services for the Company.

    

    12.        Effect of
Partial Invalidity.  The invalidity of any portion of this
Agreement shall not affect the validity of any other provision.  In
the event that any provision of this Agreement is held to be invalid, the
parties agree that the remaining provisions shall remain in full force and
effect.

    

    13.        Entire
Agreement.  This Agreement, together with the other documents
referenced herein, reflects the complete agreement between the parties regarding
the subject matter identified herein and shall supersede all other previous
agreements, either oral or written, between the parties. The parties stipulate
that neither of them, nor any person acting on their behalf has made any
representations except as are specifically set forth in this Agreement and each
of the parties acknowledges that it or he has not relied upon any representation
of any third party in executing this Agreement, but rather have relied
exclusively on it or his own judgment in entering into this
Agreement.

    

    14.        Assignment.  Employer
may assign its interest and rights under this Agreement at its sole discretion
and without approval of Executive to a successor in interest by the Employer’s
merger, consolidation or other form of business combination with or into a third
party where the Employer’s stockholders before such event do not control a
majority of the resulting business entity after such event.  All
rights and entitlements arising from this Agreement, including but not limited
to those protective covenants and prohibitions set forth in the Confidentiality,
Non-Solicitation and Non-Compete Agreement attached as Addendum A and
incorporated into this Agreement shall inure to the benefit of any purchaser,
assignor or transferee of this Agreement and shall continue to be enforceable to
the extent allowable under applicable law.  Neither this Agreement,
nor the employment status conferred with its execution is assignable or subject
to transfer in any manner by Executive.

    

    15.        Notices.  All
notices, requests, demands, and other communications shall be in writing and
shall be given by registered or certified mail, postage prepaid, a) if to the
Employer, at the Employer’s then current headquarters location, and b) if to
Executive, at the most recent address on file with the Company for Executive or
to such subsequent addresses as either party shall so designate in writing to
the other party.

     

    
      
        
          
            	 
      	
                    Executive Initials

                  
	 
      	 
      
	 
      	 
      

          

        

      

       

    

    
      
         

      

      
        7

        
          

        

      

      
         

      

    

    16.        Remedies.  If
any action at law, equity or in arbitration, including an action for declaratory
relief, is brought to enforce or interpret the provisions of this Agreement, the
prevailing party may, if the court or arbitrator hearing the dispute, so
determines, have its reasonable attorneys’ fees and costs of enforcement
recouped from the non-prevailing party.

    

    17.        Amendment/Waiver.  No
waiver, modification, amendment or change of any term of this Agreement shall be
effective unless it is in a written agreement signed by both
parties.  No waiver by the Employer of any breach or threatened breach
of this Agreement shall be construed as a waiver of any subsequent breach unless
it so provides by its terms.

    

    18.        Governing
Law, Venue and Jurisdiction.  This Agreement and all
transactions contemplated by this Agreement shall be governed by, construed, and
enforced in accordance with the laws of the State of Florida without regard to
any conflicts of laws, statutes, rules, regulations or
ordinances.  Executive consents to personal jurisdiction and venue in
the Circuit Court in and for Lee County, Florida regarding any action arising
under the terms of this Agreement and any and all other disputes between
Executive and Employer.

    

    19.        Arbitration.     Any
and all controversies and disputes between Executive and Employer arising from
this Agreement or regarding any other matter whatsoever shall be submitted to
arbitration before a single unbiased arbitrator skilled in arbitrating such
disputes under the American Arbitration Association, utilizing its Commercial
Rules.  Any arbitration action brought pursuant to this section shall
be heard in Fort Myers, Lee County, Florida.  The Circuit Court in and
for Lee County, Florida shall have concurrent jurisdiction with any arbitration
panel for the purpose of entering temporary and permanent injunctive relief, but
only with respect to any alleged breach of the Confidentiality, Non-Solicitation
and Non-Compete Agreement.

    

    20.        Headings.  The
titles to the sections of this Agreement are solely for the convenience of the
parties and shall not affect in any way the meaning or interpretation of this
Agreement.

    

    21.        Miscellaneous
Terms.  The parties to this Agreement declare and represent
that:

    

    
      	
               
      

            	
              a.

            	
              They
      have read and understand this
Agreement;

            

    

    

    
      	
               
      

            	
              b.

            	
              They
      have been given the opportunity to consult with an attorney if they so
      desire;

            

    

    

    
      	
               
      

            	
              c.

            	
              They
      intend to be legally bound by the promises set forth in this Agreement and
      enter into it freely, without duress or
  coercion;

            

    

    

    
      	
               
      

            	
              d.

            	
              They
      have retained signed copies of this Agreement for their records;
      and

            

    

    

    
      	
               
      

            	
              e.

            	
              The
      rights, responsibilities and duties of the parties hereto, and the
      covenants and agreements contained herein, shall continue to bind the
      parties and shall continue in full force and effect until each and every
      obligation of the parties under this Agreement has been
      performed.

            

    

    

    22.        Counterparts.  This Agreement
may be executed in counterparts and by facsimile, or by pdf, each of which shall
be deemed an original for all intents and purposes.

    

    Signatures
appear on the following page.

     

    
      
        
          
            	 
      	
                    Executive Initials

                  
	 
      	 
      
	 
      	 
      

          

        

      

       

    

    
      
         

      

      
        8

        
          

        

      

      
         

      

    

    IN
WITNESS WHEREOF, the parties have executed this Agreement as of the date first
written above.

    

    
      
        	
                NEOGENOMICS,
      INC., a Nevada

              
	
                Corporation

              
	 
      	 
      
	
                By:

              	
                /s/ Robert P.
      Gasparini

              
	
                Name:

              	
                Robert P. Gasparini

              
	 
      	 
      
	
                Title:

              	
                President

              
	 
      	 
      
	
                EXECUTIVE:

              
	 
      
	
                /s/ Douglass M. VanOort

              
	
                Douglas
      M. VanOort

              

      

    

    
      

      
        
          
          

        

      

      

        
          
             

          

          
            9

            
              

            

          

          
             

          

        

      

    

     

    Addendum
A

    

    CONFIDENTIALITY,
NON-SOLICITATION AND NON-COMPETE AGREEMENT

    

    This
Confidentiality, Non-Solicitation and Non-Compete Agreement (the “Agreement”)
dated this 16th day of March, 2009 is entered into by and between Douglas M.
VanOort (“Employee”)
and NeoGenomics, Inc., a Nevada corporation (“Employer”
or the “Parent
Company” and collectively with NeoGenomics, Inc., a Florida corporation
(the “Operating
Company”) and any entity that is wholly or partially owned by the Parent
Company or otherwise affiliated with the Parent Company, the “Company”).  Hereinafter,
each of the Employee or the Company maybe referred to as a “Party”
and together be referred to as the “Parties”.

    

    RECITALS:

    

    WHEREAS, the Parties have
entered into that certain employment agreement, dated March 16, 2009, that
creates an employment relationship between the Employer and Employee (the “Employment
Agreement”); and

    

    WHEREAS, pursuant to the
Employment Agreement, the Employee agreed to enter into the Company’s
Confidentiality, Non-Solicitation and Non-Compete Agreement; and

    

    WHEREAS, the Company desires
to protect and preserve its Confidential Information and its legitimate business
interests by having the Employee enter into this Agreement as part of the
Employment Agreement; and

    

    WHEREAS, the Employee desires
to establish and maintain an employment relationship with the Company and as
part of such employment relationship desires to enter into this Agreement with
the Company; and

    

    WHEREAS, the Employee
acknowledges that the terms of the Employment Agreement including, but not
limited to the Company’s commitments to the Employee with respect to base
salary, fringe benefits and stock options are sufficient consideration to the
Employee for the entry into this Agreement.

    

    NOW, THEREFORE, in
consideration of the mutual promises set forth herein and other good and
valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, the Parties agree as follows:

    

    1.           Term. Employee agree(s) that
the term of this agreement is effective upon the Effective Date (as defined in
the Employment Agreement) and shall survive and continue to be in force and
effect for two years following the termination of any employment relationship
between the Parties (“Term”),
whether termination is by the Company with or without cause, wrongful discharge,
or for any other reason whatsoever, or by the Employee.

     

    
      
        
          
            	 
      	
                    Executive Initials

                  
	 
      	 
      
	 
      	 
      

          

        

      

       

    

    
      
         

      

      
        10

        
          

        

      

      
         

      

    

    2.           Definitions.

    

    a.           The
term “Confidential
Information” as used herein shall include all business practices,
methods, techniques, or processes that:  (i) derives independent
economic value, actual or potential, from not being generally known to, and not
being readily ascertainable by proper means by, other persons who can obtain
economic value from its disclosure or use; and (ii) is the subject of efforts
that are reasonable under the circumstances to maintain its
secrecy.  Confidential Information also includes, but is not limited
to, files, letters, memoranda, reports, records, computer disks or other
computer storage medium, data, models or any photographic or other tangible
materials containing such information, Customer lists and names and other
information, Customer contracts, other corporate contracts, computer programs,
proprietary technical information and or strategies, sales, promotional or
marketing plans or strategies, programs, techniques, practices, any expansion
plans (including existing and entry into new geographic and/or product markets),
pricing information, product or service offering specifications or plans
thereof, business plans, financial information and other financial plans, data
pertaining to the Company’s operating performance, employee lists, salary
information, training manuals, and other materials and business information of a
similar nature, including information about the Company itself or any affiliated
entity, which Employee acknowledges and agrees has been compiled by the
Company's expenditure of a great amount of time, money and effort, and that
contains detailed information that could not be created independently from
public sources.  Further, all data, spreadsheets, reports, records,
know-how, verbal communication, proprietary and technical information and/or
other confidential materials of similar kind transmitted by the Company to
Employee or developed by the Employee on behalf of the Company as Work Product
(as defined in Paragraph 7) are expressly included within the definition of
“Confidential Information.”  The Parties further agree that the fact
the Company may be seeking to complete a business transaction is “Confidential
Information” within the meaning of this Agreement, as well as all notes,
analysis, work product or other material derived from Confidential
Information. Nevertheless,
Confidential Information shall not include any information of any kind which (1)
is in the possession of the Employee prior to the date of this Agreement, as
shown by the Employee’s files and records, or (2) prior or after the time of
disclosure becomes part of the public knowledge or literature, not as a result
of any violation of this Agreement or inaction or action of the receiving party,
or (3) is rightfully received from a third party without any obligation of
confidentiality; or (4) independently developed after termination without
reference to the Confidential Information or materials based thereon; or (5) is
disclosed pursuant to the order or requirement of a court, administrative
agency, or other government body; or (6) is approved for release by the
non-disclosing party.

    

    b.           The
term “Customer”
shall mean any person or entity which has purchased or ordered goods, products
or services from the Company and/or entered into any contract for products or
services with the Company within the one (1) year immediately preceding the
termination of the Employee’s employment with the Company.

    

    c.           
The term “Prospective
Customer” shall mean any person or entity which has evidenced an
intention to order products or services with the Company within one year
immediately preceding the termination of the Employee’s employment with the
Company.

    

    d.           The
term “Restricted
Area” shall include any geographical location anywhere in the United
States. If the
Restricted Area specified in this Agreement should be judged unreasonable in any
proceeding, then the period of Restricted Area shall be reduced so that the
restrictions may be enforced as is judged to be reasonable.

    

    e.           The
phrase “directly
or indirectly” shall include the Employee either on his/her own account,
or as a partner, owner, promoter, joint venturer, employee, agent, consultant,
advisor, manager, executive, independent contractor, officer, director, or a
stockholder of 5% or more of the voting shares of an entity in the Business of
Company.

    

    f.           The
term “Business”
shall mean the business of providing non-academic, for-profit cancer genetic and
molecular laboratory testing services, including, but not limited to,
cytogenetics, flow cytometry, fluorescence in-situ hybridization (“FISH”), and
morphological studies, to hematologists, oncologists, urologists, pathologists,
hospitals and other medical reference laboratories. 

     

    
      
        
          
            	 
      	
                    Executive Initials

                  
	 
      	 
      
	 
      	 
      

          

           

          
            
              
                 

              

              
                11

                
                  

                

              

              
                 

              

            

          

           

        

      

    

    3.           Duty of
Confidentiality.

    

    a.           All
Confidential Information is considered highly sensitive and strictly
confidential. The Employee agrees that at all times during the term of this
Agreement and after the termination of employment with the Company for as long
as such information remains non-public information, the Employee shall (i) hold
in confidence and refrain from disclosing to any other party all Confidential
Information, whether written or oral, tangible or intangible, concerning the
Company and its business and operations unless such disclosure is accompanied by
a non-disclosure agreement executed by the Company with the party to whom such
Confidential Information is provided, (ii) use the Confidential Information
solely in connection with his or her employment with the Company and for no
other purpose, (iii) take all reasonable precautions necessary to ensure that
the Confidential Information shall not be, or be permitted to be, shown, copied
or disclosed to third parties, without the prior written consent of the Company,
(iv) observe all security policies implemented by the Company from time to time
with respect to the Confidential Information, and (v) not use or disclose,
directly or indirectly, as an individual or as a partner, joint venturer,
employee, agent, salesman, contractor, officer, director or otherwise, for the
benefit of himself or herself or any other person, partnership, firm,
corporation, association or other legal entity, any Confidential Information,
unless expressly permitted by this Agreement.  Employee agrees that
protection of the Company’s Confidential Information constitutes a legitimate
business interest justifying the restrictive covenants contained
herein.  Employee further agrees that the restrictive covenants
contained herein are reasonably necessary to protect the Company’s legitimate
business interest in preserving its Confidential Information.

    

    b.           In
the event that the Employee is ordered to disclose any Confidential Information,
whether in a legal or regulatory proceeding or otherwise, the Employee shall
provide the Company with prompt notice of such request or order so that the
Company may seek to prevent disclosure.

    

    c.           Employee
acknowledge(s) that this "Confidential Information" is of value to the Company
by providing it with a competitive advantage over their competitors, is not
generally known to competitors of the Company, and is not intended by the
Company for general dissemination.  Employee acknowledges that this
"Confidential Information" derives independent economic value, actual or
potential, from not being generally known to, and not being readily
ascertainable by proper means by, other persons who can obtain economic value
from its disclosure or use, and is the subject of reasonable efforts to maintain
its secrecy.  Therefore, the Parties agree that all "Confidential
Information" under this Agreement constitutes “Trade
Secrets” under Section 688.002 and Chapter 812 of the Florida
Statutes.

    

    4.           Limited
Right of Disclosure.   Except as
otherwise permitted by this Agreement, Employee shall limit disclosure of
pertinent Confidential Information to Employee’s attorney, if any (“Representative(s)”),
for the sole purpose of evaluating Employee’s relationship with the
Company.  Paragraph 3 of this Agreement shall bind all such
Representative(s).

    

    5.           Return of
Company Property and Confidential Materials.   All
tangible property, including cell phones, laptop computers and other Company
purchased property, as well as all Confidential Information provided to Employee
is the exclusive property of the Company and must be returned to the Company in
accordance with the instructions of the Company either upon termination of the
Employee’s employment or at such other time as is reasonably requested by the
Company.  Employee agree(s) that upon termination of employment for
any reason whatsoever Employee shall return all copies, in whatever form,
including hard copies and computer disks, of Confidential Information to the
Company, and Employee shall delete any copy of the Confidential Information on
any computer file or database maintained by Employee and shall certify in
writing that he/she has done so.  In addition to returning all
Confidential Information to the Company as described above, Employee will
destroy any analysis, notes, work product or other materials relating to or
derived from the Confidential Information.  Any retention of
Confidential Information may constitute “civil theft” as such term is defined in
Chapter 772 of the Florida Statutes.

     

    
      
        
          
            	 
      	
                    Executive Initials

                  
	 
      	 
      
	 
      	 
      

          

        

      

       

    

    
      
         

      

      
        12

        
          

        

      

      
         

      

    

    6.           Agreement
Not To Circumvent.  Employee agrees
not to pursue any transaction or business relationship that is directly
competitive to the Business of the Company that makes use of any Confidential
Information during the Term of this Agreement, other than through the Company or
on behalf of the Company.  It is further understood and agreed that,
after the Employee’s employment with the Company has been terminated, the
Employee will direct all communications and requests from any third parties
regarding Confidential Information or Business opportunities which use
Confidential Information through the Company’s then chief executive officer or
president.  Employee acknowledges that any violation of this covenant
may subject Employee to the remedies identified in Paragraph 9 in addition to
any other available remedies.

    

    7.           Title to
Work Product.   Employee
agrees that all work products (including strategies and testing methodologies
for competing in the genetics testing industry, technical materials and
diagrams, computer programs, financial plans and other written materials,
websites, presentation materials, course materials, advertising campaigns,
slogans, videos, pictures and other materials) created or developed by the
Employee for the Company during the term of the Employee’s employment with the
Company or any successor to the Company until the date of termination of the
Employee (collectively, the “Work
Product”), shall be considered a work made for hire and that the Company
shall be the sole owner of all rights, including copyright, in and to the Work
Product.

    

    If the Work Product, or any part
thereof, does not qualify as a work made for hire, the Employee agrees to
assign, and hereby assigns, to the Company for the full term of the copyright
and all extensions thereof all of its right, title and interest in and to the
Work Product.  All discoveries, inventions, innovations, works of
authorship, computer programs, improvements and ideas, whether or not patentable
or copyrightable or otherwise protectable, conceived, completed, reduced to
practice or otherwise produced by the Employee in the course of his or her
services to the Company in connection with or in any way relating to the
Business of the Company or capable of being used or adapted for use therein or
in connection therewith shall forthwith be disclosed to the Company and shall
belong to and be the absolute property of the Company unless assigned by the
Company to another entity.

    

    Employee hereby assigns to the
Company all right, title and interest in all of the discoveries, inventions,
innovations, works of authorship, computer programs, improvements, ideas and
other work product; all copyrights, trade secrets, and trademarks in the same;
and all patent applications filed and patents granted worldwide on any of the
same for any work previously completed on behalf of the Company or work
performed under the terms of this Agreement or the Employment
Agreement.  Employee, if and whenever required to do so (whether
during or after the termination of his or her employment), shall at the expense
of the Company apply or join in applying for copyrights, patents or trademarks
or other equivalent protection in the United States or in other parts of the
world for any such discovery, invention, innovation, work of authorship,
computer program, improvement, and idea as aforesaid and execute, deliver and
perform all instruments and things necessary for vesting such patents,
trademarks, copyrights or equivalent protections when obtained and all right,
title and interest to and in the same in the Company absolutely and as sole
beneficial owner, unless assigned by the Company to another
entity.  Notwithstanding the foregoing, work product conceived by the
Employee, which is not related to the Business of the Company, will remain the
property of the Employee.

     

    
      
        
          
            	 
      	
                    Executive Initials

                  
	 
      	 
      
	 
      	 
      

          

        

      

      

        
          
             

          

          
            13

            
              

            

          

          
             

          

        

      

    

     

    8.           Restrictive
Covenant.   The Company
and its affiliated entities are engaged in the Business of providing genetic and
molecular testing services.  The covenants contained in this Paragraph
8 (the “Restrictive
Covenants”) are given and made by Employee to induce the Company to
employ Employee under the terms of the Employment Agreement, and Employee
acknowledges sufficiency of consideration for these Restrictive
Covenants.  Employee expressly covenants and agrees that, during his
or her employment and for a period of two (2) years following termination of
such employment (such period of time is hereinafter referred to as the "Restrictive
Period"), he/she will abide by the following restrictive covenants unless
an exception is specifically provided in certain situations in such Restrictive
Covenants.

    

    
      	
               
      

            	
              a.

            	
              Non-Solicitation.   Employee
      agrees and acknowledges that, during the Restrictive Period, he/she will
      not, directly or indirectly, in one or a series of transactions, as an
      individual or as a partner, joint venturer, employee, agent, salesperson,
      contractor, officer, director or otherwise, for the benefit of himself or
      herself or any other person, partnership, firm, corporation, association
      or other legal entity:

            

    

    

    
      	
               
      

            	
              (i)

            	
              solicit
      or induce any Customer or Prospective Customer of the Company to patronize
      or do business with any other company (or business) that is in the
      Business conducted by the Company in any market in which the Company does
      Business; or

            

    

    

    
      	
               
      

            	
               (ii)

            	
              request
      or advise any Customer or vendor, or any Prospective Customer or
      prospective vendor, of the Company, who was a Customer, Prospective
      Customer, vendor or prospective vendor within one year immediately
      preceding the termination of the Employee’s employment with the Company,
      to withdraw, curtail, cancel or refrain from doing Business with the
      Company in any capacity; or

            

    

     

    
      	
               
      

            	
              (iii)

            	
              recruit,
      solicit or otherwise induce any proprietor, partner, stockholder, lender,
      director, officer, employee, sales agent, joint venturer, investor,
      lessor, supplier, Customer, agent, representative or any other person
      which has a business relationship with the Company or any Affiliated
      Entity to discontinue, reduce or detrimentally modify such employment,
      agency or business relationship with the Company;
  or

            

    

    

    
      	
               
      

            	
              iv)

            	
              employ
      or solicit for employment any person or agent who is then (or was at any
      time within twelve (12) months prior to the date Employee or such entity
      seeks to employ such person) employed or retained by the
      Company.  Notwithstanding the foregoing, to the extent the
      Employee works for a larger firm or corporation after his termination from
      the Company and he does not have any personal knowledge and/or control
      over the solicitation of or the employment of a Company employee or agent,
      then this provision shall not be
enforceable.

            

    

    

    
      	
               
      

            	
              b.

            	
              Non-Competition.   Employee
      agrees and acknowledges that, during the Restrictive Period, he will not,
      directly or indirectly, for himself , or on behalf of others, as an
      individual on Employee's own account, or as a partner, joint venturer,
      employee, agent, salesman, contractor, officer, director or otherwise, for
      himself  or any other person, partnership, firm, corporation,
      association or other legal entity enter into, engage in or accept
      employment from any business that is in the Business of the Company in the
      Restricted Area during his last twelve months of employment. The parties
      agree that this non-competition provision is intended to cover situations
      where a future business opportunity in which the Employee is engaged or a
      future employer of the Employee is selling the same or similar products
      and services in the Business which may compete with the Company’s products
      and services to Customers and Prospective Customers of the Company in the
      Restricted Area.  This provision shall not cover future business
      opportunities or employers of the Employee that sell different types of
      products or services in the Restricted Area so long as such future
      business opportunities or employers are not in the Business of the
      Company.  In addition, this provision shall not cover the
      investment activities of Summer Street Capital, with whom the Employee is
      affiliated as a partner, so long as the Employee is not in any way
      associated or involved with any investments of Summer Street Capital that
      may be competitive with the Business of the
  Company.

            

    

     

    
      
        
          
            	 
      	
                    Executive Initials

                  
	 
      	 
      
	 
      	 
      

          

           

          
            
              
                 

              

              
                14

                
                  

                

              

              
                 

              

            

          

           

        

      

    

    
      	
               
      

            	
              c.

            	
              Acknowledgements of
      Employee.

            

    

    

    
      	
               
      

            	
              (i)

            	
              The
      Employee understands and acknowledges that any violation of the
      Restrictive Covenants shall constitute a material breach of this Agreement
      and the Employment Agreement, and it may cause irreparable harm and loss
      to the Company for which monetary damages will be an insufficient
      remedy.  Therefore, the Parties agree that in addition to any
      other remedy available, the Company will be entitled to the relief
      identified in Paragraph No. 9
below.

            

    

    

    
      	
               
      

            	
              (ii)

            	
              The
      Restrictive Covenants shall be construed as agreements independent of any
      other provision in this Agreement and the existence of any claim or cause
      of action of Employee against the Company shall not constitute a defense
      to the enforcement of these Restrictive
  Covenants.

            

    

    

    
      	
               
      

            	
              (iii)

            	
              Employee
      agrees that the Restrictive Covenants are reasonably necessary to protect
      the legitimate business interests of the
  Company.

            

    

    

    
      	
               
      

            	
              (iv)

            	
              Employee
      agrees that the Restrictive Covenants may be enforced by the Company’s
      successor in interest by way of merger, business combination or
      consolidation where a majority of the surviving entity is not owned by
      Company’s shareholders who owned a majority of the Company’s voting shares
      prior to such transaction and Employee acknowledges and agrees that
      successors are intended beneficiaries of this
  Agreement.

            

    

    

    
      	
               
      

            	
              (v)

            	
              Employee
      agrees that if any portion of the Restrictive Covenants is held by a court
      of competent jurisdiction to be unreasonable, arbitrary or against public
      policy for any reason, such shall be divisible as to time, geographic area
      and line of business and shall be enforceable as to a reasonable time,
      area and line of business.

            

    

    

    
      	
               
      

            	
              (vi)

            	
              Employee
      acknowledges that any violations of the Restrictive Covenants, in any
      capacity identified herein, may be a material breach of this Agreement and
      may subject the Employee, and/or any individual(s), partnership,
      corporation, joint venture or other type of business with whom the
      Employee is then affiliated or employed, to monetary and other
      damages.

            

    

    

    
      	
               
      

            	
              (vii)

            	
              Employee
      agrees that any failure of the Company to enforce the Restrictive
      Covenants against any other employee, for any reason, shall not constitute
      a defense to enforcement of the Restrictive Covenants against the
      Employee.

            

    

     

    9.           Specific
Performance; Injunction.   The Parties
agree and acknowledge that the restrictions contained in Paragraphs 1-8 are
reasonable in scope and duration and are necessary to protect the
Company.  If any provision of Paragraphs 1-8 as applied to any party
or to any circumstance is judged by a court to be invalid or unenforceable, the
same shall in no way affect any other circumstance or the validity or
enforceability of any other provision of this Agreement.  If any such
provision, or any part thereof, is held to be unenforceable because of the
duration of such provision or the area covered thereby, the court making such
determination shall have the power to reduce the duration and/or area of such
provision, and/or to delete specific words or phrases, and in its reduced form,
such provision shall then be enforceable and shall be enforced.

     

    
      
        
          
            	 
      	
                    Executive Initials

                  
	 
      	 
      
	 
      	 
      

          

           

          
            
              
                 

              

              
                15

                
                  

                

              

              
                 

              

            

          

           

        

      

    

    Any
unauthorized use or disclosure of Confidential Information in violation of
Paragraphs 2-7 above or violation of the Restrictive Covenant in Paragraph 8
shall constitute a material breach of this Agreement and will cause irreparable
harm and loss to the Company for which monetary damages may be an insufficient
remedy.  Therefore, in addition to any other remedy available, the
Company will be entitled to all of the civil remedies provided by Florida
Statutes, including:

    

    
      	
               
      

            	
              a.

            	
              Temporary
      and permanent injunctive relief, without the necessity of posting a bond,
      restraining Employee or Representatives and any other person, partnership,
      firm, corporation, association or other legal entity acting in concert
      with Employee from any actual or threatened unauthorized disclosure or use
      of Confidential Information, in whole or in part, or from rendering any
      service to any other person, partnership, firm, corporation, association
      or other legal entity to whom such Confidential Information in whole or in
      part, has been disclosed or used or is threatened to be disclosed or used;
      and

            

    

    

    
      	
               
      

            	
              b.

            	
              Temporary
      and permanent injunctive relief, without the necessity of posting a bond,
      restraining the Employee from violating, directly or indirectly, the
      restrictions of the Restrictive Covenant in any capacity identified in
      Paragraph 8, supra, and restricting third parties from aiding and abetting
      any violations of the Restrictive Covenant;
and

            

    

    

    
      	
               
      

            	
              c.

            	
              Compensatory
      damages, including actual loss from misappropriation and unjust
      enrichment.

            

    

    

    Notwithstanding
the foregoing, the Company acknowledges and agrees that the Employee will not be
liable for the payment of any damages or fees owed to the Company through the
operation of Paragraphs 9c above, unless and until a court of competent
jurisdiction has determined conclusively that the Company or any successor is
entitled to such recovery.

    

    Nothing
in this Agreement shall be construed as prohibiting the Company from pursuing
any other legal or equitable remedies available to it for actual or threatened
breach of the provisions of Paragraphs 1 – 8 of this Agreement, and the
existence of any claim or cause of action by Employee against the Company shall
not constitute a defense to the enforcement by the Company of any of the
provisions of this Agreement.  The Company and its Affiliated Entities
have fully performed all obligations entitling it to the covenants of Paragraphs
1 – 8 of this Agreement and therefore such prohibitions are not executory or
otherwise subject to rejection under the bankruptcy code.

    

    10.         Governing
Law, Venue and Personal Jurisdiction.   This
Agreement shall be governed by, construed and enforced in accordance with the
laws of state of Florida without regard to any statutory or common-law provision
pertaining to conflicts of laws.  The parties agree that courts of
competent jurisdiction in Lee County, Florida and the United States District
Court for the Southern District of Florida shall have concurrent jurisdiction
for purposes of entering temporary, preliminary and permanent injunctive relief
and with regard to any action arising out of any breach or alleged breach of
this Agreement.  Employee waives personal service of any and all
process upon Employee and consents that all such service of process may be made
by certified or registered mail directed to Employee at the address stated in
the signature section of this Agreement, with service so made deemed to be
completed upon actual receipt thereof.  Employee waives any objection
to jurisdiction and venue of any action instituted against Employee as provided
herein and agrees not to assert any defense based on lack of jurisdiction or
venue.

     

    
      
        
          
            	 
      	
                    Executive Initials

                  
	 
      	 
      
	 
      	 
      

          

        

      

      

        
          
             

          

          
            16

            
              

            

          

          
             

          

        

      

    

     

    11.        Successors
and Assigns.   This
Agreement shall be binding upon and inure to the benefit of the Parties hereto
and may not be assigned by Employee. This Agreement shall inure to the benefit
of Company’s s successors.

    

    12.        Entire
Agreement.   This
Agreement is the entire agreement of the Parties with regard to the matters
addressed herein, and supersedes all prior negotiations, preliminary agreements,
and all prior and contemporaneous discussions and understandings of the
signatories in connection with the subject matter of this Agreement, except
however, that this Agreement shall be read in pari materia with the
Employment Agreement executed by Employee.  This Agreement may be
modified only by written instrument signed by the Company and
Employee.

    

    13.        Severability.   In case any
one or more provisions contained in this Agreement shall, for any reason, be
held invalid, illegal or unenforceable in any respect, such invalidity,
illegality or unenforceability shall not affect any other provision hereof and
this Agreement shall be construed as if such invalid, illegal were unenforceable
provision had not been contained herein.

    

    14.        Waiver. The waiver by the
Company of a breach or threatened breach of this Agreement by Employee cannot be
construed as a waiver of any subsequent breach by Employee unless such waiver so
provides by its terms.  The refusal or failure of the Company to
enforce any specific restrictive covenant in this Agreement against Employee, or
any other person for any reason, shall not constitute a defense to the
enforcement by the Company of any other restrictive covenant provision set forth
in this Agreement.

    

    
      15.      
 Consideration.   Employee
expressly acknowledges and agrees that the execution by the Company of the
Employment Agreement with the Employee constitutes full, adequate and sufficient
consideration to Employee for the covenants of Employee under this
Agreement.

    

    

    
      16.      
 Notices
.   All
notices required by this Agreement shall be in writing, shall be personally
delivered or sent by U.S. Registered or Certified Mail, return receipt
requested, and shall be addressed to the signatories at the addresses shown on
the signature page of this Agreement.

    

    

    
      17.      
 Acknowledgements.   Employee
acknowledge(s) that he  has reviewed this Agreement prior to signing
it, that he  knows and understands the contents, purposes and effect
of this Agreement, and that he  has been given a signed copy of this
Agreement for his  records. Employee further acknowledges and agrees
that he  has entered into this Agreement freely, without any duress or
coercion.

    

    

    18.      
 Counterparts.   This
Agreement may be executed in counterparts, by facsimile or pdf each of which
shall be deemed an original for all intents and purposes.

    

    IN
WITNESS WHEREOF, THE UNDERSIGNED STATE THAT THEY HAVE CAREFULLY READ THIS
AGREEMENT AND KNOW AND UNDERSTAND THE CONTENTS THEREOF AND THAT THEY AGREE TO BE
BOUND AND ABIDE BY THE REPRESENTATIONS, COVENANTS, PROMISES AND WARRANTIES
CONTAINED HEREIN.

    

    
      	
              By:

            	
              /s/ Douglas VanOort

            	
              3/16/2009

            	 
      
	 
      	
              Employee
      Signature

            	
              Date

            	 
      

    

     

    
      
        
          
          

        

      

      

      
        
          
             

          

          
            17

            
              

            

          

          
             

          

        

      

       

    

    
      
        
          
            	
                    Employee
      Name:

                  	
                    Douglas VanOort

                  
	 
      	 
      
	
                    Employee
      Address:

                  	
                    3275 Regatta Rd

                  
	 
      	 
      
	 
      	
                    Naples, FL 34103

                  
	 
      	 
      
	 	 

          

        

      

    

     

    NeoGenomics,
Inc.

    
      12701
Commonwealth Drive, Suite #9

    

    
      Fort
Myers, FL 33913

    

    

    
      
        	
                By:

              	
                /s/ Robert Gasparini

              	 
      	
                3/16/2009

              
	 
      	 
      	 
      	
                Date

              

      

    

    

    
      	
              Name:

            	
              Robert Gasparini

            	 
      
	 
      	 
      	 
      
	
              Title:

            	
              President

            	 
      

    

     

    
      
        
          
          

        

      

       

    

    
      
         

      

      
        18Unassociated Document

    Exhibit
10.35

     

    [Confidential
Treatment Requested.  Confidential portions of this document have
been

    redacted
and have been separately filed with the Securities and Exchange
Commission]

     

    SECOND AMENDMENT TO
REVOLVING CREDIT AND SECURITY AGREEMENT

     

    THIS
SECOND AMENDMENT TO REVOLVING CREDIT AND SECURITY AGREEMENT (this “Agreement”) is entered into on
this 14th day of
April 2009 (the “Effective
Date”), by and among NEOGENOMICS LABORATORIES,
INC., a Florida corporation formerly known as NeoGenomics, Inc. (“Borrower”), NEOGENOMICS, INC., a Nevada
corporation (“Guarantor”, together with
Borrower, each individually a “Credit Party” and
collectively, the “Credit
Parties”), and CAPITALSOURCE FINANCE LLC, a
Delaware limited liability company, as agent for the lender under the Credit
Agreement referred to below (“Agent”).

     

    RECITALS

     

    A.       
   Credit Parties and CapitalSource Finance LLC (together with
its successors and assigns, CSF”) have entered into that
certain Revolving Credit and Security Agreement, dated as of February 1, 2008 as
amended by that certain First Amendment to Revolving Credit and Security
Agreement dated November 3, 2008 (as may be amended, restated, supplemented, or
otherwise modified from time to time, the “Credit
Agreement”).

     

    B.        
   Pursuant to Section 15.2 of the
Credit Agreement, CSF assigned the Revolving Facility to CapitalSource Bank
(“Lender”).

     

    C.       
    Pursuant to Section 15.12 of the
Credit Agreement, Lender has designated Agent as its agent for taking certain
actions under the Loan Agreement.

     

    D.       
   Credit Parties have requested that Agent agree to make certain
amendments to the Credit Agreement.  Agent has agreed to this request
on the conditions set forth in this Agreement.

     

    E.       
    Pursuant to the terms and conditions of this Agreement,
Credit Parties and Agent have agreed to amend certain provisions of the Credit
Agreement.

     

    NOW,
THEREFORE, in consideration of the premises herein contained and other good and
valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, the parties, intending to be legally bound, agree as
follows:

     

    AGREEMENT

     

    ARTICLE
I -
DEFINITIONS

     

    1.01       Definitions.  The
following definition is added to Section 1.2 of the Credit Agreement in the
appropriate alphabetical order:

    
      
         

      

      
        
        

        
          

        

      

      
         

      

    

    “Second Amendment
Date” shall mean April 14, 2009”.

     

    1.02     
  General
Terms.  Capitalized terms used in this Agreement are defined in
the Credit Agreement, as amended hereby, unless otherwise stated.

     

    ARTICLE
II– WAIVER AND
CONSENT

     

    2.01        Waiver.

     

    (a)          The
following Events of Default have occurred and are continuing under the Credit
Agreement:

     

    (i)           the
failure of Borrower to comply with the Fixed Charge Coverage Ratio covenant set
forth in Section 1 of Annex I to the Loan Agreement for the Test Period ending
December 31, 2008;

     

    (ii)          the
failure of Borrower to notify Lender of Borrower’s name change to Neogenomics
Laboratories, Inc. and to obtain Lender’s prior consent to the related amendment
to Borrower’s Articles of Incorporation;

     

    (iii)         the
failure of the Credit Parties to obtain Lender’s prior written consent to the
amendment of the Guarantor’s By-Laws to allow for a Board of Directors of up to
eight members;

     

    (iv)         the
failure of the Credit Parties to notify Lender the filing by Borrower of a
complaint against Thomas Schofield, a former employee of the Borrower ((i),
(ii), (iii) and (iv) collectively hereinafter referred to as the “Specified Events of
Default”).

     

    (b)         Subject
to the conditions contained herein, Agent hereby waives the Specified Events of
Default.  Except as expressly set forth herein with respect to the
Specified Events of Default, this letter agreement shall not be deemed to be a
waiver of any Default or Events of Default.  The waiver set forth
herein shall not preclude the future exercise of any other right, power, or
privilege available to Agent or Lender whether under the Credit Agreement, the
Loan Documents or otherwise.

     

    2.02        Consent
to Alter By-Laws of the Borrower.  Notwithstanding
the terms of Section
9.7 of the Credit Agreement to the contrary, Agent consents to the
amendment and restatement of the Bylaws of Borrower in the form and substance of
the proposed by-laws attached hereto as Exhibit A.

     

    2.03        Consent
to Alter By-Laws of the Guarantor.  Notwithstanding
the terms of Section
9.7 of the Credit Agreement to the contrary, Agent consents to the
amendment and restatement of the Bylaws of Guarantor in the form and substance
of the proposed by-laws attached hereto as Exhibit B.

    
      
         

      

      
        2

        
          

        

      

      
         

      

    

    ARTICLE
III -
AMENDMENTS

     

    3.01        Amendments
to Annex I of the Credit Agreement.  Effective as of the
Effective Date, Annex
I of the Credit Agreement is hereby amended by:

     

    (a)          Deleting
Section 3 of Annex
I in its entirety and replacing it with the following:

     

    
      	
               
      

            	
              3)

            	
              Minimum
      Liquidity

            

    

     

    For the
period from the Second Amendment Date through and including December 31, 2009,
the Minimum Liquidity shall not be less than $500,000.

     

    (b)         deleting
the definition of Fixed Charge Coverage Ratio in Annex I in its
entirety and replacing it with the following:

     

    “Fixed Charge Coverage
Ratio” shall mean for Borrower collectively on a consolidated basis (a)
as of any date of determination occurring during the period from the Closing
Date through and including the Second Amendment Date the ratio of (i) Adjusted
EBITDA for the Test Period ended as of such date to (ii) Fixed charges for the
Test Period ended on such date; provided, that, solely for
purposes of calculating the Fixed Charge Coverage Ratio for the Test Periods
ending January 31, 2009 and February 28, 2009, the amount of Adjusted EBITDA for
such Test Periods shall be increased by an amount equal to the sum of (A)
$90,000 with respect to recruiting expenses, plus (B) $309,400
with respect to write-offs of bad debt, plus (C) $56,000 with
respect to bonus accrual, (b) as of any date of determination occurring during
the period after the Second Amendment Date to and including December 31, 2009
the ratio of (i) the sum of Adjusted EBITDA for the Test Period ended as of
such date plus
an amount equal to the sum of unrestricted cash on hand, unrestricted Cash
Equivalents and unused Availability as of the last day of the Test Period ended
as of such date, to (ii) Fixed Charges for the Test Period ended as of such
date; and (c) as of any date of determination occurring after December 31, 2009,
the ratio of (i) Adjusted EBITDA for the Test Period ended as of such date
to (ii) Fixed Charges for the Test Period ended as of such date.

     

    (c)          deleting
the definition of Fixed Charges in Annex I in its
entirety and replacing it with the following:

    
      
         

      

      
        3

        
          

        

      

      
         

      

    

    “Fixed
Charges” shall mean, for any period, the sum of the following for Borrower
collectively on a consolidated basis for such period:  (a) Total Debt
Service, (b) un-financed Capital Expenditures paid in cash, (c) income taxes
paid in cash or accrued, and (d) dividends and Distributions paid or accrued or
declared (except for Accumulated Distributions from previous Accumulated
Distribution Fiscal Quarters); reduced by the amount of any equity contributions
received by the Borrower in cash during such period; provided that the amount of
such reduction shall not exceed the amount of unfinanced Capital Expenditures
paid for by Borrower in cash during such period.

     

    3.02        Amendment
to Definition of Permitted Indebtedness.  Effective as of
the Effective Date, subsection (iii) of the definition of “Permitted
Indebtedness” set forth in Section 1.2 of the Credit Agreement is hereby amended
and restated in its entirety to read as follows:

     

    “(iii)
Capitalized Lease Obligations incurred after the Closing Date and Indebtedness
incurred to purchase Goods and secured by purchase money Liens constituting
Permitted Liens: (A) in aggregate amount outstanding at any time not to exceed
$4,000,000, provided, that,  (1) the debt service
for such Indebtedness shall not exceed $1,500,000 for any twelve (12) month
period and (2) upon the incurrence of such Indebtedness and after giving effect
thereto no Default or Event of Default shall exist and be continuing and (B) in
an aggregate amount in excess of $4,000,000, provided, that, (1) ten (10)
Business Days prior to the incurrence of such Indebtedness Borrower shall have
provided pro forma financial statements along with any other supporting
documentation required by Lender evidencing that Borrower would have been in
compliance with the financial covenants set forth on Annex 1 hereto for the
immediately preceding Test Period (as defined on Annex 1 hereto), if such
Indebtedness had been incurred on the first day of such Test Period, (2) prior
to the incurrence of such Indebtedness Borrower shall have received Lender’s
written confirmation of its agreement with such pro forma financial statements;
and (3) upon the incurrence of such Indebtedness and after giving effect thereto
no Default or Event of Default shall exist and be continuing,”

     

    3.03        Representation
and Warranties Updates.  Effective as of
the Effective Date, Article VII of the Credit Agreement is hereby amended
by:

     

    (a)          Subsection
(iv) of Section 7.5 is hereby deleted and replaced its entirety with the
following:

     

    “(iv) a
party to any contract with any Affiliate other than as set forth on Schedule 7.5, except
for employment agreements, option agreements, confidentiality agreements,
non-solicitation/non-competition agreements and other compensation, severance or
consulting arrangements with directors or officers in the ordinary course of
business that are on terms at least as favorable to such Credit Party as would
be the case in an arm’s length transaction between unrelated parties of equal
bargaining power and under which payments due from Credit Parties are not more
than $500,000 per annum per arrangement.

    
      
         

      

      
        4

        
          

        

      

      
         

      

    

    (b)          Subsection
(i) of Section 7.16 is hereby deleted and replaced its entirety with the
following:

     

    “(i)
there are no existing or proposed agreements,  arrangements,
understandings or transactions between any Credit Party and any of such Credit
Party’s officers, members, managers, directors, stockholders, partners, other
interest holders, employees or Affiliates or any members of their respective
immediate families, other than employment agreements, option agreements,
confidentiality agreements, non-solicitation/non-competition agreements and
other compensation, severance or consulting arrangements with directors or
officers in the ordinary course of business that are on terms at least as
favorable to such Credit Party as would be the case in an arm’s length
transaction between unrelated parties of equal bargaining power and under which
payments due from Credit Parties are not more than $500,000 per annum per
arrangement.”

     

    3.04        Schedules.

     

    The
schedules to the Credit Agreement are deleted and replaced in their entirety
with the amended and restated schedules attached to this Agreement as Exhibit
C.

     

    ARTICLE
IV- CONDITIONS
PRECEDENT

     

    4.01        Conditions
to Effectiveness.  The effectiveness
of this Agreement against Lender is subject to the satisfaction of the following
conditions precedent in a manner satisfactory to Agent in its sole discretion,
unless specifically waived in writing by Agent:

     

    (a)      
   Agent shall have received this Agreement duly executed by each
party thereto; and

     

    (b)         Agent
shall have received the Amendment Fee (as hereinafter defined).

     

    ARTICLE
V-
RATIFICATIONS, REPRESENTATIONS AND WARRANTIES

     

    5.01        Ratifications.  The terms and
provisions set forth in this Agreement shall modify and supersede all
inconsistent terms and provisions set forth in the Credit Agreement and the Loan
Documents, and, except as expressly modified and superseded by this Agreement,
the terms and provisions of the Credit Agreement and the Loan Documents are
ratified and confirmed and shall continue in full force and
effect.  The Credit Parties hereby ratify and confirm that the Liens
granted under the Credit Agreement secure all obligations and indebtedness now,
hereafter or from time to time made by, owing to or arising in favor of Lender
pursuant to the Loan Documents (as now, hereafter, or from time to time
amended).  Credit Parties and Agent agree that the Credit Agreement
and the Loan Documents, as amended hereby, shall continue to be legal, valid,
binding and enforceable in accordance with their respective
terms.

    
      
         

      

      
        5

        
          

        

      

      
         

      

    

    5.02        Representations
and Warranties.  The Credit
Parties hereby represent and warrant to Agent that:

     

    (a)          The
representations and warranties made by Borrower (other than those made as of a
specific date) contained in the Credit Agreement, as amended hereby, and each
Loan Document are true and correct in all material respects (except that, for
those representations and warranties already qualified by concepts of
materiality, those representations and warranties shall be true and correct in
all respects) on and as of the date hereof and as of the date of execution
hereof as though made on and as of each such date;

     

    (b)         No
Default or Event of Default under the Credit Agreement, as amended hereby, has
occurred and is continuing, except for the Specified Events of
Default;

     

    (c)         Other
than as contemplated hereby, Borrower has not amended its certificate of
incorporation or bylaws (or any other equivalent governing agreement or
document), as applicable, since the date of the Credit Agreement.

     

    ARTICLE
VI- AMENDMENT
FEE

     

    6.01        Amendment
Fee.  Borrower agrees to pay to Lender $25,000 as an amendment
fee (the “Amendment
Fee”), which fee shall be due and payable on the date
hereof.  Borrower hereby authorizes Agent to charge such fee as an
Advance on the date hereof and shall be fully earned by Lender when so
charged.

     

    ARTICLE
VII-
MISCELLANEOUS PROVISIONS

     

    7.01        Survival
of Representations and Warranties.  All
representations and warranties made in the Credit Agreement, or any Loan
Document, including, without limitation, any document furnished in connection
with this Agreement, shall survive the execution and delivery of this Agreement
and the Loan Documents, and no investigation by Agent or Lender or any closing
shall affect the representations and warranties or the right of Agent or Lender
to rely upon them.

     

    7.02        Reference
to Credit Agreement.  Each of the
Credit Agreement and the Loan Documents, and any and all Loan Documents,
documents or instruments now or hereafter executed and delivered pursuant to the
terms hereof or pursuant to the terms of the Credit Agreement, as amended
hereby, are hereby amended so that any reference in the Credit Agreement and
such Loan Documents to the Credit Agreement shall mean a reference to the Credit
Agreement, as amended hereby.

     

    7.03        Expenses
of Agent or Lender.  As provided in
the Credit Agreement, the Credit Parties agree to pay on demand all costs and
expenses incurred by each of Agent and Lender in connection with the
preparation, negotiation, and execution of this Agreement and the Loan Documents
executed pursuant hereto and any and all amendments, modifications, and
supplements thereto, including, without limitation, the reasonable costs and
fees of Agent and Lender’s legal counsel, and all costs and expenses incurred by
Agent and Lender in connection with the enforcement or preservation of any
rights under the Credit Agreement, as amended hereby, or any Loan Documents,
including, without, limitation, the reasonable costs and fees of Agent and
Lender’s legal counsel.

    
      
         

      

      
        6

        
          

        

      

      
         

      

    

    7.04        Severability.  Any provision of
this Agreement held by a court of competent jurisdiction to be invalid or
unenforceable shall not impair or invalidate the remainder of this Agreement and
the effect thereof shall be confined to the provision so held to be invalid or
unenforceable.

     

    7.05        Successors
and Assigns.  This Agreement is
binding upon and shall inure to the benefit of Agent, Lender and Credit Parties
and their respective successors and assigns, except that Credit Parties may not
assign or transfer any of their rights or obligations hereunder without the
prior written consent of Agent.

     

    7.06        Counterparts.  This Agreement
may be executed in one or more counterparts, each of which when so executed
shall be deemed to be an original, but all of which when taken together shall
constitute one and the same instrument.  Any signature delivered by a
party by facsimile or other electronic transmission shall be deemed to be an
original signature hereto.

     

    7.07        Effect of
Waiver.  No consent or
waiver, express or implied, by Agent or Lender to or for any breach of or
deviation from any covenant or condition by Borrower shall be deemed a consent
to or waiver of any other breach of the same or any other covenant, condition or
duty.

     

    7.08        Headings.  The headings,
captions, and arrangements used in this Agreement are for convenience only and
shall not affect the interpretation of this Agreement.

     

    7.09    
   Applicable
Law.  THIS AGREEMENT
AND ALL LOAN DOCUMENTS EXECUTED PURSUANT HERETO SHALL BE DEEMED TO HAVE BEEN
MADE AND TO BE PERFORMABLE IN AND SHALL BE GOVERNED BY AND CONSTRUED IN
ACCORDANCE WITH THE CHOICE OR LAW SET FORTH IN THE CREDIT
AGREEMENT.

     

    7.10        Final
Agreement.  THE CREDIT
AGREEMENT AND THE LOAN DOCUMENTS, EACH AS AMENDED HEREBY, REPRESENT THE ENTIRE
EXPRESSION OF THE PARTIES WITH RESPECT TO THE SUBJECT MATTER HEREOF ON THE DATE
THIS AGREEMENT IS EXECUTED.  THE CREDIT AGREEMENT AND THE LOAN
DOCUMENTS, AS AMENDED HEREBY, MAY NOT BE CONTRADICTED BY EVIDENCE OF PRIOR,
CONTEMPORANEOUS OR SUBSEQUENT ORAL AGREEMENTS OF THE PARTIES.  THERE
ARE NO UNWRITTEN ORAL AGREEMENTS BETWEEN THE PARTIES.  NO
MODIFICATION, RESCISSION, WAIVER, RELEASE OR AGREEMENT OF ANY PROVISION OF THIS
AGREEMENT SHALL BE MADE, EXCEPT BY A WRITTEN AGREEMENT SIGNED BY THE CREDIT
PARTIES AND AGENT.

    
      
         

      

      
        7

        
          

        

      

      
         

      

    

    7.11        Release.  EACH CREDIT PARTY
HEREBY ACKNOWLEDGES THAT IT HAS NO DEFENSE, COUNTERCLAIM, OFFSET,
CROSS-COMPLAINT, CLAIM OR DEMAND OF ANY KIND OR NATURE WHATSOEVER THAT CAN BE
ASSERTED TO REDUCE OR ELIMINATE ALL OR ANY PART OF ITS LIABILITY TO REPAY THE
“OBLIGATIONS” OR TO SEEK AFFIRMATIVE RELIEF OR DAMAGES OF ANY KIND OR NATURE
FROM AGENT OR LENDER.  EACH CREDIT PARTY HEREBY VOLUNTARILY AND
KNOWINGLY RELEASES AND FOREVER DISCHARGES AGENT, LENDER, AND ANY OF ITS OR THEIR
RESPECTIVE PREDECESSORS, AGENTS, ATTORNEYS, EMPLOYEES, AFFILIATES, SUCCESSORS
AND ASSIGNS, FROM ALL POSSIBLE CLAIMS, DEMANDS, ACTIONS, CAUSES OF ACTION,
DAMAGES, COSTS, EXPENSES, AND LIABILITIES WHATSOEVER, KNOWN OR UNKNOWN,
ANTICIPATED OR UNANTICIPATED, SUSPECTED OR UNSUSPECTED, FIXED, CONTINGENT, OR
CONDITIONAL, AT LAW OR IN EQUITY, ORIGINATING IN WHOLE OR IN PART ON OR BEFORE
THE DATE THIS AGREEMENT IS EXECUTED, WHICH BORROWER MAY NOW OR HEREAFTER HAVE
AGAINST AGENT, LENDER, OR ANY OF ITS RESPECTIVE PREDECESSORS, ATTORNEYS, AGENTS,
EMPLOYEES, AFFILIATES, SUCCESSORS AND ASSIGNS, IF ANY, AND IRRESPECTIVE OF
WHETHER ANY SUCH CLAIMS ARISE OUT OF CONTRACT, TORT, VIOLATION OF LAW OR
REGULATIONS, OR OTHERWISE, AND ARISING FROM ANY “LOANS”, INCLUDING, WITHOUT
LIMITATION, ANY CONTRACTING FOR, CHARGING, TAKING, RESERVING, COLLECTING OR
RECEIVING INTEREST IN EXCESS OF THE HIGHEST LAWFUL RATE APPLICABLE, THE EXERCISE
OF ANY RIGHTS AND REMEDIES UNDER THE CREDIT AGREEMENT OR LOAN DOCUMENTS, AND
NEGOTIATION FOR AND EXECUTION OF THIS AGREEMENT.

    

    [REMAINDER
OF PAGE INTENTIONALLY LEFT BLANK]

    
      
         

      

      
        8

        
          

        

      

      
         

      

    

    IN
WITNESS WHEREOF, this Agreement has been executed and is effective as of the
date first written above.

    

    
      	 
      	
              BORROWER:

            
	 
      	 
      
	 
      	
              NEOGENOMICS
      LABORATORIES, INC.,

              a
      Florida corporation

            
	 
      	 
      
	 
      	
              By:

            	
              /s/Steven C. Jones

            
	 
      	
              Name:

            	
              Steven C. Jones

            
	 
      	
              Title:

            	
              Chief Financial Officer

            
	 
      	 
      
	 
      	
              GUARANTOR:

            
	 
      	 
      
	 
      	
              NEOGENOMICS,
      INC., a Nevada corporation

            
	 
      	 
      	 
      
	 
      	
              By:

            	
              /s/Steven C. Jones

            
	 
      	
              Name:

            	
              Steven C. Jones

            
	 
      	
              Title:

            	
              Chief Financial Officer

            
	 
      	 
      
	 
      	
              CAPITALSOURCE
      FINANCE LLC, as Agent

            
	 
      	 
      
	 
      	
              By:

            	
              /s/Arturo J. Velez

            
	 
      	
              Name:

            	
              Arturo J. Velez

            
	 
      	
              Title:

            	
              Authorized
  Signatory

            

    

     

    
      
         

      

      
        9

        
          

        

      

      
         

      

    

    
      EXHIBIT
A

    

    
      Bylaws
of Borrower

    

    [see
attached]

    
      
         

      

      
        
        

        
          

        

      

      
         

      

    

    AMENDED
AND RESTATED

    

    BYLAWS

    

    OF

    

    NEOGENOMICS
LABORATORIES, INC.

    (a
Florida Corporation)

    

    ARTICLE
I.  MEETINGS OF SHAREHOLDERS

    

    Section
1.    Annual
Meeting.  The annual meeting of the Shareholders of NeoGenomics
Laboratories, Inc. (the “Corporation”) shall
be held at the time and place designated by the Board of Directors of the
Corporation.  The annual meeting shall be held within four months
after the close of the Corporation's fiscal year.  The annual meeting
of Shareholders for any year shall be held no later than thirteen months after
the last preceding annual meeting of Shareholders.  Business
transacted at the annual meeting shall include the election of Directors of the
Corporation.

     

    Section 2.    Special
Meetings.  Special meetings of the Shareholders shall be held
when directed by the President or the Board of Directors, or when requested in
writing by the holders of not less than ten percent of all the shares entitled
to vote at the meeting.  A meeting requested by Shareholders shall be
called for a date not less than ten nor more than sixty days after the request
is made, unless the Shareholders requesting the meeting designate a later
date.  The call for the meeting shall be issued by the Secretary,
unless the President, the Board of Directors, or the Shareholders requesting the
meeting shall designate another person to do so.

     

    Section 3.  Place.  Meetings
of Shareholders may be held within or without the State of Florida.

     

    Section 4.    Notice.  Written
notice stating the place, day and hour of the meeting and, in the case of a
special meeting, the purpose or purposes for which the meeting is called shall
be delivered not less than ten nor more than sixty days before the meeting,
either personally or by first class mail, by or at the direction of the
President, the Secretary, or the Officer or persons calling the meeting to each
Shareholder of record entitled to vote at such meeting.  If mailed,
such notice shall be deemed to be delivered when deposited in the United States
mail addressed to the Shareholder at his address as it appears on the stock
transfer books of the Corporation, with postage thereon prepaid.

     

    Section 5.   Notice of Adjourned
Meetings.  When a meeting is adjourned to another time or
place, it shall not be necessary to give any notice of the adjourned meeting if
the time and place to which the meeting is adjourned are announced at the
meeting at which the adjournment is taken, and at the adjourned meeting any
business may be transacted that might have been transacted on the original date
of the meeting.  if, however, after the adjournment the Board of
Directors fixes a new record date for the adjourned meeting, a notice of the
adjourned meeting shall be given as provided in this section to each Shareholder
of record on the new record date entitled to vote at such
meeting.

    
      
         

      

      
        
        

        
          

        

      

      
         

      

    

    Section 6.  Fixing Record
Date.  For the purpose of determining Shareholders entitled to
notice of or to vote at any meeting of Shareholders or any adjournment thereof,
or entitled to receive payment of any dividend, or in order to make a
determination of Shareholders for any other purpose, the Board of Directors
shall fix in advance a date as the record date for any determination of
Shareholders, such date in any case to be not more than sixty days and, in case
of a meeting of Shareholders, not less than ten days, prior to the date on which
the particular action requiring such determination of Shareholders is to be
taken.  When a determination of Shareholders entitled to vote at any
meeting of Shareholders has been made as provided in this section, such
determination shall apply to any adjournment thereof, unless the Board of
Directors fixes a new record date for the adjourned meeting.

     

    Section 7.  Voting
Record.  The Officers or agent having charge of the stock
transfer books for shares of the Corporation shall make, at least ten days
before each meeting of Shareholders, a complete list of the Shareholders
entitled to vote at such meeting or any adjournment thereof, with the address of
and the number and class and series, if any, of shares held by
each.  The list, for a period of ten days prior to such meeting, shall
be kept on file at the registered office of the Corporation, at the principal
place of business of the Corporation or at the office of the transfer agent or
registrar of the Corporation and any Shareholder shall be entitled to inspect
the list at any time during the usual business hours.  The list shall
also be produced and kept open at the time and place of the meeting and shall be
subject to the inspection of any Shareholder at any time during the
meeting.

     

    If the requirements of this section
have not been substantially complied with, the meeting on demand of any
Shareholder in person or by proxy, shall be adjourned until the requirements are
complied with.  If no such demand is made, failure to comply with the
requirements of this section shall not affect the validity of any action taken
at such meeting.

    

    Section 8.  Shareholder Quorum and
Voting.  A majority of the shares entitled to vote, represented
in person or by proxy, shall constitute a quorum at a meeting of
Shareholders.  When a specified item of business is required to be
voted on by a class or series of stock, a majority of the shares of such class
or series shall constitute a quorum for the transaction of such item of business
by that class or series.

     

    If a quorum is present, the affirmative
vote of the majority of the shares represented at the meeting and entitled to
vote on the subject matter shall be the act of the Shareholders unless otherwise
provided by law.

     

    After a quorum has been established at
a Shareholders' meeting, the subsequent withdrawal of Shareholders, so as to
reduce the number of Shareholders entitled to vote at the meeting below the
number required for a quorum, shall not affect the validity of any action taken
at the meeting or any adjournment thereof.

    

    Section 9.  Voting of
Shares.  Each outstanding share, regardless of class, shall be
entitled to one vote on each matter submitted to a vote at a meeting of
Shareholders.

    
      
         

      

      
        
        

        
          

        

      

      
         

      

    

    Treasury shares, shares of stock of the
Corporation owned by another corporation the majority of the voting stock of
which is owned or controlled by the Corporation, and shares of stock of the
Corporation held by it in a fiduciary capacity shall not be voted, directly or
indirectly, at any meeting, and shall not be counted in determining the total
number of outstanding shares at any given time.

     

    A Shareholder may vote either in person
or by proxy executed in writing by the Shareholder or his duly authorized
attorney-in-fact.

     

    At each election for Directors every
Shareholder entitled to vote at such election shall have the right to vote, in
person or by proxy, the number of shares owned by him for as many persons as
there are Directors to be elected at that time and for whose election he has a
right to vote.

     

    Shares standing in the name of another
corporation, domestic or foreign, may be voted by the Officer, agent, or proxy
designated by the Bylaws of the corporate Shareholder; or, in the absence of any
applicable Bylaw, by such person as the Board of Directors of the corporate
Shareholder may designate.  Proof of such designation may be made by
presentation of a certified copy of the Bylaws or other instrument of the
corporate Shareholder.  In the absence of any such designation, or in
case of conflicting designation by the corporate Shareholder, the Chairman of
the Board, Executive Chairman, the President, any Vice President, the Secretary
and the Treasurer of the corporate Shareholder shall be presumed to possess, in
that order, authority to vote such shares.

     

    Shares held by an administrator,
executor, guardian or conservator may be voted by him, either in person or by
proxy, without a transfer of such shares into his name.  Shares
standing in the name of a trustee may be voted by him, either in person or by
proxy, but no trustee shall be entitled to vote shares held by him without a
transfer of such shares into his name.

     

    Shares standing in the name of a
receiver may be voted by such receiver, and shares held by or under the control
of a receiver may be voted by such receiver without the transfer thereof into
his name if authority so to do be contained in an appropriate order of the court
by which such receiver was appointed.

     

    A Shareholder whose shares are pledged
shall be entitled to vote such shares until the shares have been transferred
into the name of the pledgee, and thereafter the pledgee or his nominee shall be
entitled to vote the shares so transferred.

     

    On and after the date on which a
written notice of redemption of redeemable shares has been mailed to the holders
thereof and a sum sufficient to redeem such shares has been deposited with a
bank or trust company with irrevocable instruction and authority to pay the
redemption price to the holders thereof upon surrender of certificates therefor,
such shares shall not be entitled to vote on any matter and shall not be deemed
to be outstanding shares.

     

    Section 10.  Proxies.  Every
Shareholder entitled to vote at a meeting of Shareholders or to express consent
or dissent without a meeting or any Shareholder's duly authorized
attorney-in-fact may authorize another person or persons to act for him by
proxy.

    
      
         

      

      
        
        

        
          

        

      

      
         

      

    

    Every proxy must be signed by the
Shareholder or his attorney-in-fact.  No proxy shall be valid after
the expiration of eleven months from the date thereof unless otherwise provided
in the proxy.  Every proxy shall be revocable at the pleasure of the
Shareholder executing it, except as otherwise provided by law.

     

    The authority of the holder of a proxy
to act shall not be revoked by the incompetence or death of the Shareholder who
executed the proxy unless, before the authority is exercised, written notice of
an adjudication of such incompetence or of such death is received by the
corporate officer responsible for maintaining the list of
Shareholders.

     

    If a proxy for the same shares confers
authority upon two or more persons and does pot otherwise provide, a majority of
them present at the meeting, or if only one is present then that one, may
exercise all the powers conferred by the proxy; but if the proxy holders present
at the meeting are equally divided as to the right and manner of voting in any
particular case, the voting of such shares shall be prorated.

     

    If a proxy expressly provides, any
proxy holder may appoint in writing a substitute to act in his
place.

     

    Section 11.  Voting
Trusts.  Any number of Shareholders of the Corporation may
create a voting trust for the purpose of conferring upon a trustee or trustees
the right to vote or otherwise represent their shares, as provided by
law.  Where the counterpart of a voting trust agreement and the copy
of the record of the holders of voting trust certificates has been deposited
with the Corporation as provided by law, such documents shall be subject to the
same right of examination by a Shareholder of the Corporation, in person or by
agent or attorney, as are the books and records of the Corporation, and such
counterpart and such copy of such record shall be subject to examination by any
holder of record of voting trust certificates either in person or by agent or
attorney, at any reasonable time for any proper purpose.

     

    Section 12.  Shareholders'
Agreements.  Two or more Shareholders of the Corporation may
enter into an agreement or agreements providing for the exercise of voting
rights in the manner provided in the agreement(s) or relating to any phase of
the affairs of the Corporation as provided by law.  Nothing therein
shall impair the right of the Corporation to treat the Shareholders of record as
entitled to vote the shares standing in their names.

     

    Section 13.  Action Without a
Meeting.  Any action required to be taken at any annual or
special meeting of Shareholders of the Corporation or any action which may be
taken at any annual or special meeting of Shareholders, may be taken without a
meeting, without prior notice, and without a vote if a consent in writing,
setting forth the action so taken, shall be signed by the holders of outstanding
stock having not less than the minimum number of votes that would be necessary
to authorize or take such action at a meeting at which all shares entitled to
vote thereon were present and voted.  If any class of shares is
entitled to vote thereon as a class, such written consent shall be required of
the holders of a majority of the shares of each class entitled to vote as a
class thereon and of the total shares entitled to vote thereon.

    
      
         

      

      
        
        

        
          

        

      

      
         

      

    

    Within ten (10) days after first
obtaining such authorization by written consent, notice must be given to those
Shareholders who have not consented in writing.  The notice shall
fairly summarize the material features of the authorized action and, if the
action be a merger, consolidation, or sale or exchange of assets for which
dissenters rights are provided, the notice shall contain a clear statement of
the right of Shareholders dissenting therefrom to be paid the fair value of
their shares upon compliance with the Florida Statutes provision concerning
dissenters rights of Shareholders.

     

    ARTICLE
II.  DIRECTORS

     

    Section 1.  Function.  All
corporate powers shall be exercised by or under the authority of, and the
business and affairs of the Corporation shall be managed under the direction of,
the Board of Directors.

     

    Section 2.  Qualification.  Directors
need not be residents of this state or Shareholders of the
Corporation.

     

    Section 3.  Compensation.  The
Board of Directors shall have authority to fix the compensation of
Directors.

     

    Section 4.  Duties of
Directors.  A Director shall perform his duties as a Director,
including his duties as a member of any committee of the Board upon which he may
serve, in good faith, in a manner he reasonably believes to be in the best
interests of the Corporation, and with such care as an ordinarily prudent person
in a like position would use under similar circumstances.

     

    In performing his duties, a Director
shall be entitled to rely on information, opinions, reports or statements,
including financial.  statements and other financial data, in each
case prepared or presented by:

     

    (a)  one
or more Officers or employees of the Corporation whom the Director reasonably
believes to be reliable and competent in the matters presented,

     

    (b)  counsel,
public accountants or other persons as to matters which the Director reasonably
believes to be within such person's professional or expert competence,
or

     

    (c)  a
committee of the Board upon which he does not serve, duly designated in
accordance with a provision of the Articles of Incorporation or the Bylaws, as
to matters within its designated authority, which committee the Director
reasonably believes to merit confidence.

     

    A Director shall not be considered to
be acting in good faith if he has actual knowledge concerning the matter in
question that would cause such reliance described above to be
unwarranted.

     

    A person who performs his duties in
compliance with this section shall have no liability by reason of being or
having been a Director of the Corporation.

     

    Section 5.  Presumption of
Assent.  A Director of the Corporation who is present at a
meeting of its Board of Directors at which action on any corporate matter is
taken shall be presumed to have assented to the action taken unless he votes
against such action or abstains from voting in respect thereto because of an
asserted conflict of interest.

    
      
         

      

      
        
        

        
          

        

      

      
         

      

    

    Section 6.  Director Conflicts of
Interest.  No contract or other transaction between the
Corporation and one or more of its Directors or any other corporation, firm,
association or entity in which one or more of the Directors are Directors or
Officers or are financially interested, shall be either void or voidable because
of such relationship or interest or because such Director or Directors are
present at the meeting of the Board of Directors or a committee thereof which
authorizes, approves or ratifies such contract or transaction or because his or
their votes are counted for such purpose, if:

     

    (a)  the
fact of such relationship or interest is disclosed or known to the Board of
Directors or committee which authorizes, approves or ratifies the contract or
transaction by a vote or consent sufficient for the purpose without counting the
votes or consents of such interested Directors; or

     

    (b)  the
fact of such relationship or interest is disclosed or known to the Shareholders
entitled to vote and they authorize, approve or ratify such contract or
transaction by vote or written consent; or

     

    (c)  the
contract or transaction is fair and reasonable as to the Corporation at the time
it is authorized by the Board, a committee or the Shareholders.

     

    Common or interested directors may be
counted in determining the presence of a quorum at a meeting of the Board of
Directors or a committee thereof which authorizes, approves or ratifies such
contract or transaction.

    

    Section 7.  Executive and Other
Committees.  The Board of Directors, by resolution adopted by a
majority of the full Board of Directors, may designate from among its members an
executive committee and one or more other committees each of which, to the
extent provided in such resolution shall have and may exercise all the authority
of the Board of Directors, except that no committee shall have the authority
to:

     

    (a)  approve
or recommend to Shareholders actions or proposals required by law to be approved
by Shareholders;

     

    (b)  designate
candidates for the office of Director, for purposes of proxy solicitation or
otherwise;

     

    (c)  fill
vacancies on the Board of Directors or any committee thereof;

     

    (d)  amend
the Bylaws;

     

    (e)  authorize
or approve the reacquisition of shares unless pursuant to a general formula or
method specified by the Board of Directors; or

    
      
         

      

      
        
        

        
          

        

      

      
         

      

    

     

    (f)  authorize
or approve the issuance or sale of, or any contract to issue or sell, shares or
designate the terms of a series of a class of shares, except that the Board of
Directors" having acted regarding general authorization for the issuance or sale
of shares, or any contract therefor, and, in the case of a series, the
designation thereof, may, pursuant to a general formula or method specified by
the Board of Directors, by resolution or by adoption of a stock option or other
plan, authorize a committee to fix the terms of any contract for the sale of the
shares and to fix the terms upon which such shares may be issued or sold,
including, without limitation, the price, the rate or manner of payment of
dividends, provisions for redemption, sinking fund, conversion, voting or
preferential rights, and provisions for other features of a class of shares, or
a series of a class of shares, with full power in such committee to adopt any
final resolution setting forth all the terms thereof and to authorize the
statement of the terms of a series for filing with the Department of
State.

     

    The Board of Directors, by resolution
adopted in accordance with this section, may designate one or more Directors as
alternate members of any such committee, who may act in the place and stead of
any absent member or members at any meeting of such committee.

     

    Section 8.  Place of
Meetings.  Regular and special meetings by the Board of
Directors may be held within or without the State of Florida.

     

    Section 9.  Time, Notice and Call of
Meetings.  Regular meetings of the Board of Directors shall be
held without notice immediately following the annual meeting of
Shareholders.  Written notice of the time and place of special
meetings of the Board of Directors shall be given to each Director by either
personal delivery, telegram, facsimile or email at least two (2) days before the
meeting or by notice mailed to the Director at least five days before the
meeting.

     

    Notice of a meeting of the Board of
Directors need not be given to any Director who signs a waiver of notice either
before or after the meeting.  Attendance of a Director at a meeting
shall constitute a waiver of notice of such meeting and waiver of any and all
objections to the place of the meeting, the time of the meeting, or the manner
in which it has been called or convened, except when a Director states, at the
beginning of the meeting, any objection to the transaction of business because
the meeting is not lawfully called or convened.

     

    Neither the business to be transacted
at, nor the purpose of, any regular or special meeting of the Board of Directors
need be specified in the notice or waiver of notice of such
meeting.

     

    A majority of the Directors present,
whether or not a quorum exists, may adjourn any meeting of the Board of
Directors to another time and place.  Notice of any such adjourned
meeting shall be given to the Directors who were not present at the time of the
adjournment and, unless the time and place of the adjourned meeting are
announced at the time of the adjournment, to the other Directors.

     

    Meetings of the Board of Directors may
be called by the Chairman of the Board, by the Executive Chairman, the President
of the Corporation, or by any two Directors.

     

    Members of the Board of Directors may
participate in a meeting of such Board by means of a conference telephone or
similar communications equipment by means of which all persons participating in
the meeting can hear each other at the same time.  Participation by
such means shall constitute presence in person at a meeting.

    
      
         

      

      
        
        

        
          

        

      

      
         

      

    

     

    Section 10.  Action Without a
Meeting.  Any action required to be taken at a meeting of the
Directors of the Corporation, or any action which may be taken at a meeting of
the Directors or a committee thereof, may be taken without a meeting if a
consent in writing, setting forth the action so to be taken, signed by all of
the Directors, or all the members of the committee, as the case may be, is filed
in the minutes of the proceedings of the Board or of the
committee.  Such consent shall have the same effect as a unanimous
vote.

     

    Section 11.  Directors
Emeritus.  The Board of Directors, by resolution adopted by a
majority of the full Board of Directors, may, from time to time, designate and
appoint one or more persons who have contributed in a significant way to the
success of the Corporation and who have previously served as directors of the
Corporation or whose terms are expiring and who have not been nominated for
reelection to the Board of Directors as “Directors
Emeritus”.  Directors Emeritus may be recognized as such in any public
announcements, advertisements, brochures and other descriptive material
concerning the Corporation and shall be privileged to attend meetings of the
Board of Directors and to participate in the consideration and discussion of
matters coming before the Board of Directors, but they shall have no official
status as directors, their presence at any meeting shall be disregarded for the
purpose of determining the presence of a quorum, and they shall have no vote on
matters determined by the Board of Directors.  The Board of Directors
shall have authority to fix the compensation of Directors Emeritus, including
reimbursement for expenses incurred in attending meetings of the Board of
Directors.

     

    Section 12.  Size of Board of
Directors.  The number of directors shall be determined from
time to time by resolution of the Board of Directors, provided the Board of
Directors shall consist of at least one member.  No reduction of
the authorized number of directors shall have the effect of removing any
director before that director’s term of office expires.

    

    ARTICLE
III.  OFFICERS

     

    Section 1.  Officers.  The
Officers of the Corporation shall consist of an Executive Chairman, a President,
a Secretary and a Treasurer, each of whom shall be elected by the Board of
Directors.  Such other Officers and Assistant Officers and agents
as-may be deemed necessary may be elected or appointed by the Board of Directors
from time to time.  Any two or more offices may be held by the same
person.

     

    Section 2.  Authority and
Duties.  All Officers of the Corporation shall respectively
have such authority and perform such duties in the management of the business of
the Corporation as may be designated from time to time by the Board of Directors
and, to the extent not so provided, as generally pertain to their respective
offices, subject to the control of the Board of Directors.

    

    Section 3.  Removal of
Officers.  Any Officer or agent elected or appointed by the
Board of Directors may be removed by the Board of Directors, with or without
cause, whenever in its judgment the best interests of the Corporation will be
served thereby.

    
      
         

      

      
        
        

        
          

        

      

      
         

      

    

    Any Officer or agent elected by the
Shareholders may be removed only by vote of the Shareholders, unless the
Shareholders shall have authorized the Directors to remove such officer or
agent.

     

    Any vacancy, however occurring, in any
office may be filled by the Board of Directors, unless the Bylaws shall have
expressly reserved such power to the Shareholders.

     

    Removal of any Officer shall be without
prejudice to the contract rights, if any, of the person so removed; however,
election or appointment of an Officer or agent shall not of itself create
contract rights.

     

    Section 4.  Compensation.  The
compensation of the Executive Chairman, the President, the Secretary, the
Treasurer and such other Officers elected or appointed by the Board of Directors
shall be fixed by the Board of Directors and may be changed from time to time by
a majority vote of the Board.  The fact that an Officer is also a
Director shall not preclude such person from receiving compensation as either a
Director or Officer, nor shall it affect the validity of any resolution by the
Board of Directors fixing such compensation.  The Executive Chairman
shall have authority to fix the salaries of all employees of the Corporation
other than Officers elected or appointed by the Board of Directors.

     

    ARTICLE IV.  STOCK
CERTIFICATES

     

    Section 1.  Issuance.  Every
holder of shares in the Corporation shall be entitled to have a certificate,
representing all shares to which he is entitled.  No certificate shall
be issued for any share until such share is fully paid.

     

    Section 2.  Form.  Certificates
representing shares in the Corporation shall be signed by the President or any
Vice President and the Secretary or any Assistant Secretary and may be sealed
with the seal of the Corporation or a facsimile thereof.  The
signatures of the President or Vice President and the Secretary or Assistant
Secretary may be facsimiles if the certificate is manually signed on behalf of a
transfer agent or a registrar, other than the Corporation itself or an employee
of the Corporation.  In case any Officer who signed or whose facsimile
signature has been placed upon such certificate shall have ceased to be such
Officer before such certificate is issued, it may be issued by the Corporation
with the same effect as if he were such Officer at the date of its
issuance.

     

    Every certificate representing shares
which are restricted as to the sale, disposition or other transfer of such
shares shall state that such shares are restricted as to transfer and shall set
forth or fairly summarize upon the certificate, or shall state that the
Corporation will furnish to any Shareholder upon request and without charge a
full statement of, such restrictions.

     

    Each certificate representing shares
shall state upon the face thereof: the name of the Corporation; that the
Corporation is organized under the laws of this state; the name of the person or
persons to whom issued; the number and class of shares, and the designation of
the series, if any, which such certificate represents; and the par value of each
share represented by such certificate, or a statement that the shares are
without par value.

    
      
         

      

      
        
        

        
          

        

      

      
         

      

    

    Section 3.  Transfer of
Stock.  The Corporation shall register a stock certificate
presented to it for transfer if the certificate is properly endorsed by the
holder of record or by his duly authorized attorney.

     

    Section 4.  Lost, Stolen, or Destroyed
Certificates.  The Corporation shall issue a new stock
certificate in the place of any certificate previously issued if the holder of
record of the certificate (a) makes proof in affidavit form that it has been
lost, destroyed or wrongfully taken; (b) requests the issue of a new certificate
before the Corporation has notice that the certificate has been acquired by a
purchaser for value in good faith and without notice of any adverse claim; and
(c) satisfies any other reasonable requirements imposed by the Corporation,
including bond in such form as the Corporation may direct, to indemnify the
Corporation, the transfer agent, and registrar against any claim that may be
made on account of the alleged loss, destruction or theft of a
certificate.

     

    ARTICLE V.  BOOKS
AND RECORDS

     

    Section 1.  Books and
Records.  The Corporation shall keep correct and complete books
and records of account and shall keep minutes of the proceedings of its
Shareholders, Board of Directors and committees of Directors.

     

    The Corporation shall keep at its
registered office or principal place of business, or at the office of its
transfer agent or registrar, a record of its Shareholders, giving the names and
addresses of all Shareholders, and the number, class and series, if any, of the
shares held by each.

     

    Any books, records and minutes may be
in written form or in any other form capable of being converted into written
form within a reasonable time.

     

    Section 2.  Shareholders' Inspection
Rights.  Any person who shall have been a holder of record of
ten percent (10%) of the outstanding shares or of voting trust certificates of
capital stock therefor at least six months immediately preceding his demand or
shall be the holder of record of, or the holder of record of voting trust
certificates for, at least five percent of the outstanding shares of any class
or series of the Corporation, upon written demand stating the purpose thereof,
shall have the right to examine, in person or by agent or attorney, at any
reasonable time or times, for any proper purpose its relevant books and records
of accounts, minutes and records of Shareholders and to make extracts
therefrom.

     

    Section 3.  Financial
Information.  Not later than four (4) months after the close of
each fiscal year, the Corporation shall prepare a balance sheet showing in
reasonable detail the financial condition of the Corporation as of the close of
its fiscal year, and a profit and loss statement showing the results of the
operations of the Corporation during its fiscal year.  This
requirement may be modified by a resolution of the Shareholders not later than
four (4) months after the close of each fiscal year.

     

    Upon written request of any Shareholder
or holder of voting trust certificates for shares of the Corporation, the
Corporation shall mail to such Shareholder or holder of voting trust
certificates a copy of the most recent such balance sheet and profit and loss
statement.

     

    The balance sheets and profit and loss
statements shall be filed in the registered office of the Corporation in this
state, shall be kept for at least five years, and shall be subject to inspection
during business hours by any Shareholder or holder of voting trust certificates,
in person or by agent.

    
      
         

      

      
        
        

        
          

        

      

      
         

      

    

     

    ARTICLE
VI.  DIVIDENDS

     

    The Board of Directors of the
Corporation may, from time to time, declare and the Corporation may pay
dividends on its shares in cash, property or its own shares, except when the
Corporation is insolvent or when the payment thereof would render the
Corporation insolvent or when the declaration or payment thereof would be
contrary to any restrictions contained in the Articles of Incorporation, subject
to the following provisions:

     

    (a)  Dividends
in cash or property may be declared and paid, except as otherwise provided in
this section, only out of the unreserved and unrestricted earned surplus of the
Corporation or out of capital surplus, howsoever arising, but each dividend paid
out of capital surplus shall be identified as a distribution of capital surplus,
and the amount per share paid from such surplus shall be disclosed to the
Shareholders receiving the same concurrently with the distribution.

     

    (b)  Dividends
may be declared and paid in the Corporation's own treasury shares.

     

    (c)  Dividends
may be declared and paid in the Corporation's own authorized but unissued shares
out of any unreserved and unrestricted surplus of the Corporation upon the
following conditions:

     

    (1)  If
a dividend is payable in shares having a par value, such shares shall be issued
at not less than the par value thereof and there shall be transferred to stated
capital at the time such dividend is paid an amount of surplus equal to the
aggregate par value of the shares to be issued as a dividend.

     

    (2)  If
a dividend is payable in shares without par value, such shares shall be issued
at such stated value as shall be fixed by the Board of Directors by resolution
adopted at the time such dividend is declared, and there shall be transferred to
stated capital at the time such dividend is paid an amount of surplus equal to
the aggregate stated value so fixed in respect of such shares; and the amount
per share so transferred to stated capital shall be disclosed to the
Shareholders receiving such dividend concurrently with the payment
thereof.

     

    (3)  No
dividend payable in shares of any class shall be paid to the holders of shares
of any other class unless the Articles of Incorporation so provide or such
payment is authorized by the affirmative vote or the written consent of the
holders of at least a majority of the outstanding shares of the class in which
the payment is to be made.

     

    (d)  A
split-up or division of the issued shares of any class into a greater number of
shares of the same class without increasing the stated capital of the
Corporation shall not be construed to be a share dividend within the meaning of
this section.

     

    ARTICLE
VII.  CORPORATE SEAL

     

    The Board of Directors shall provide a
corporate seal which shall be circular in form and shall have inscribed thereon
the following:

    
      
         

      

      
        
        

        
          

        

      

      
         

      

    

    

    NEOGENOMICS
LABORATORIES, INC.

    

    ARTICLE
VIII.  INDEMNIFICATION

     

    Section 1.  Certain
Definitions.  For the purposes of this Section, certain terms
and phrases used herein shall have the meanings set forth below:

     

    (a)  The
term "enterprise" shall include, but not be limited to, any employee benefit
plan.

     

    (b)  An
"executive" shall mean any person, including a volunteer, who is or was a
director or officer of the Corporation or who is or was serving at the request
of the Corporation as a director or officer of another corporation, partnership,
joint venture, trust or other enterprise.

     

    (c)  The
term "expenses" shall include, but not be limited to, all costs and expenses
(including attorneys' fees and paralegal expenses) paid or incurred by an
executive, in, for or related to a proceeding or in connection with
investigating, preparing to defend, defending, being a witness in or
participating in a proceeding, including such costs and expenses incurred on
appeal.  Such attorneys' fees shall include, but not be limited to (a)
attorneys' fees incurred by an executive in any and all judicial or
administrative proceedings, including appellate proceedings, arising out of or
related to a proceeding; (b) attorneys' fees incurred in order to interpret,
analyze or evaluate that person's rights and remedies in a proceeding or under
any contracts or obligations which are the subject of such proceeding; and (c)
attorneys' fees to negotiate with counsel with any claimants, regardless of
whether formal legal action is taken against him.

     

    (d)  The
term "liability" shall include, but not be limited to, the obligation to pay a
judgment, settlement, penalty or fine (including an excise tax assessed with
respect to any employee benefit plan), and expenses actually and reasonably
incurred with respect to a proceeding.

     

    (e)  The
term "proceeding" shall include, but not be limited to, any threatened, pending
or completed action, suit or other type of proceeding, whether civil, criminal,
administrative or investigative and whether formal or informal, including, but
not limited to, an action by or in the right of any corporation of any type or
kind, domestic or foreign, or of any partnership, joint venture, trust, employee
benefit plan or other enterprise, whether predicated on foreign, federal, state
or local law, to which an executive is a party by reason of the fact that he is
or was or has agreed to become a director or officer of the Corporation or is
now or was serving at the request of the Corporation as a director or officer of
another corporation, partnership, joint venture, trust or other
enterprise.

     

    (f)  The
phrase "serving at the request of the Corporation" shall include, but not be
limited to, any service as a director or officer of the Corporation that imposes
duties on such person, including duties related to an employee benefit plan and
its participants or beneficiaries.

    
      
         

      

      
        
        

        
          

        

      

      
         

      

    

     

    (g)  The
phrase "not opposed to the best interests of the Corporation" describes the
actions of a person who acts in good faith and in a manner which he reasonably
believes to be in the best interests of the Corporation or the participants and
beneficiaries of an employee benefit plan.

    

    Section 2.  Primary
Indemnification.  The Corporation shall indemnify to the
fullest extent permitted by law, and shall advance expenses therefor, to any
executive who was or is a party to a proceeding against any liability incurred
in such proceeding, including any appeal thereof, unless a court of competent
jurisdiction establishes by judgment or other final adjudication that his
actions, or omissions to act, were material to the cause of action so
adjudicated and constitute: (a) a violation of the criminal law, unless the
executive had reasonable cause to believe his conduct was lawful or had no
reasonable cause to believe his conduct was unlawful; (b) a transaction from
which the executive derived an improper personal benefit; (c) in a case of
director, a circumstance under which the liability provisions of Section
607.0834; Florida Statutes, or any successor provision, are applicable; or (d)
willful misconduct or conscious disregard for the best interests of the
Corporation in a proceeding by or in the right of the Corporation to procure a
judgment in its favor or in a proceeding by or in the right of a
shareholder.  Notwithstanding the failure to satisfy conditions (a)
through (d) of this Section, the Corporation shall nevertheless indemnify an
executive pursuant to Sections 4 or 5 hereof unless a determination is
reasonably and promptly made pursuant to Section 3 hereof that the executive did
not meet the applicable standard of conduct set forth in Sections 4 or 5 of this
Article.

     

    Section 3.  Determination of Right of
Indemnification in Certain Cases.  Any indemnification under
Sections 4 or 5 of this Article (unless ordered by a court) shall be made by the
Corporation unless a determination is reasonably and promptly made that the
executive did not meet the applicable standard of conduct set forth in Sections
4 or 5 of this Article.  Such determination shall be made by: (a) the
Board of Directors by a majority vote of a quorum consisting of directors who
were not parties to such proceeding; (b) if such a quorum is not obtainable or,
even if obtainable, by majority vote of a committee duly designated by the Board
of Directors (in which directors who are parties may participate) consisting
solely of two or more directors not at the time parties to the proceeding; (c)
by independent counsel (i) selected by the Board of Directors prescribed in
subparagraph (a) or the committee prescribed in subparagraph (b), or (ii) if a
quorum of the directors cannot be obtained under subparagraph (a), and the
committee cannot be designated under subparagraph (b), selected by majority vote
of the full Board of Directors (in which directors who are parties may
participate); or (d) by the shareholders by a majority vote of a quorum
consisting of shareholders who are not parties to such proceeding, or if no such
quorum is attainable, by a majority vote of the shareholders who were not
parties to such proceeding.  If the determination of the
permissibility of indemnification is made by independent legal counsel as set
forth in subparagraph (c) above, the other persons specified in this Section 3
shall evaluate the reasonableness of expenses.

     

    Section 4.  Proceeding Other Than By Or
In The Right of The Corporation.  The Corporation shall
indemnify any executive who was or is a party to any proceeding (other than an
action by, or in the right of, the Corporation) against liability in connection
with such proceeding, including any appeal thereof, if he acted in good faith
and in a manner he reasonably believed to be in, or not opposed to, the best
interests of the Corporation and, with respect to any criminal proceeding, had
no reasonable cause to believe his conduct was unlawful.  The
termination of any proceeding by judgment, order, settlement or conviction or
upon a plea of nolo contendere or its equivalent shall not, of itself, create a
presumption that the person did not act in good faith and in a manner which he
reasonably believed to be in, or not opposed to, the best interests of the
Corporation or, with respect to any criminal proceeding, had reasonable cause to
believe that his conduct was unlawful.

    
      
         

      

      
        
        

        
          

        

      

      
         

      

    

    Section 5.  Proceeding By Or In The
Right Of The Corporation. The Corporation shall indemnify any executive
who was or is' a party to any proceeding by or in the right of the Corporation
to procure a judgment in its favor against expenses and amounts paid in
settlement not exceeding, in the judgment of the Board of Directors, the
estimated expense of litigating the proceeding to conclusion, actually and
reasonably incurred in connection with the defense or settlement of such
proceeding, including any appeal thereof, if such person acted in good faith and
in manner which he reasonably believed to be in, or not opposed to, the best
interests of the Corporation, except that no indemnification shall be made under
this Section 5 in respect to any claim, issue or matter as to which such person
shall have been adjudged to be liable unless, and only to the extent that, the
court in which such proceeding was brought, or any other court of competent
jurisdiction, shall determine upon application that, despite the adjudication of
liability but in view of all circumstances of the case, such person is fairly
and reasonably entitled to indemnity for such expenses which such court shall
deem proper.

     

    Section 6.  Indemnification Against
Expenses of Successful Party.  Notwithstanding the other
provisions of this Section, to the extent that an executive is successful on the
merits or otherwise, including the dismissal of an action without prejudice or
the settlement of an action without admission of liability, in defense of any
proceeding or in defense of any claim, issue or matter therein, the Corporation
shall indemnify such executive against all expenses incurred in connection with
such defense.

     

    Section 7.  Advancement of
Expenses.  Notwithstanding anything in the Corporation's
Articles of Incorporation, these bylaws or any agreement to the contrary, if so
requested by an executive, the Corporation shall advance (within two (2)
business days of such request) any and all expenses relating to a proceeding (an
"expense
advance"), upon the receipt of a written undertaking by or on behalf of
such person to repay such expense advance if a judgment or other final
adjudication adverse to such person (as to which all rights of appeal have been
exhausted or lapsed) establishes that he, with respect to such proceeding, is
not eligible for indemnification under the provisions of this
Section.  Expenses incurred by other employees or agents of the
Corporation may be paid in advance upon such terms and conditions as the Board
of Directors deems appropriate.

     

    Section 8.  Right of Executive to
Indemnification Upon Application; Procedures Upon
Application.  Any indemnification or advancement of expenses
under this Section shall be made promptly upon the written request of the
executive, unless, with respect to a request under Section 4 or 5, a
determination is reasonably and promptly made under Section 3 of this Article
that such executive did not meet the applicable standard of conduct set forth in
Section 4 or 5 of this Article.  The right to indemnification or
advances as granted by this Section shall be enforceable by the executive in any
court of competent jurisdiction, if the claim is improperly denied, in whole or
in part, or if no disposition of such claim is made promptly.  The
executive's expenses incurred in connection with successfully establishing his
right to indemnification or advancement of expenses, in whole or in part, under
this Section shall also be indemnified by the Corporation.

    
      
         

      

      
        
        

        
          

        

      

      
         

      

    

    Section 9.  Court Ordered
Indemnification.  Notwithstanding the failure of the
Corporation to provide indemnification due to a failure to satisfy the
conditions of Section 2 of this Article, and despite any contrary determination
by the Corporation in the specific case under Sections 4 or 5 of this Article,
an executive of the Corporation who is or was a party to a proceeding may apply
for indemnification or advancement of expenses, or both, to the court conducting
the proceeding, to the circuit court, or to another court of competent
jurisdiction, and such court may order indemnification and advancement of
expenses, including expenses incurred in seeking court ordered indemnification
or advancement of expenses, if the court determines that:

     

    (a)  The
executive is entitled to indemnification or advancement of expenses, or both,
under this Section; or

     

    (b)  The
executive is fairly and reasonably ;entitled to indemnification or advancement
of expenses, or both, in view of all the relevant circumstances, regardless of
whether such person met any applicable standards of conduct set forth in this
Section.

     

    Section 10.  Partial Indemnity,
etc.  If an executive is entitled under any provisions of these
Bylaws to indemnification by the Corporation for some or a portion of the
expenses, judgments, fines, penalties, excise taxes and amounts paid or to be
paid in settlement of a proceeding, but not, however, for all of the total
amount therefor, the Corporation shall nevertheless indemnify such person for
the portion thereof to which he is entitled.  In connection with any
determination by the Board of Directors or arbitration that an executive is not
entitled to be indemnified hereunder, the burden shall be on the Corporation to
establish that he is not so entitled.

     

    Section 11.  Other Rights and
Remedies.  Indemnification and advancement of expenses provided
by this Section: (a) shall not be deemed exclusive of any other rights to which
an executive seeking indemnification may be entitled under any statute, Bylaw,
agreement, vote of Shareholders or disinterested directors or otherwise, both as
to action in his official capacity and as to action in any other capacity while
holding such office; (b) shall continue as to a person who has ceased to be an
executive; and (c) shall inure to the benefit of the heirs, executors and
administrators of such a person.  It is the intent of these Bylaws to
provide the maximum indemnification possible under applicable law.  To
the extent applicable law or the Articles of Incorporation of the Corporation,
as in effect on the date hereof or at any time in the future, permit greater
indemnification than is provided for in these Bylaws, the executive shall enjoy
by these Bylaws the greater benefits so afforded by such law or provision of the
Articles of Incorporation, and these Bylaws and the exceptions to
indemnification set forth herein, to the extent applicable, shall be deemed
amended without any further action by the Corporation to grant such greater
benefits.  All rights to indemnification under this Section shall be
deemed to be provided by a contract between the Corporation and the executive
who serves in such capacity at any time while these Bylaws and other relevant
provisions of the Florida Business Corporation Act and other applicable law, if
any, are in effect.  Any repeal or modification thereof shall not
affect any rights or obligations then existing.

     

    Section 12. Insurance.  By
resolution passed by the Board of Directors, the Corporation may purchase and
maintain insurance on behalf of any person who is or was an executive against
any liability asserted against him and incurred by him in any such capacity, or
arising out of his status as such, whether or not the Corporation would have the
power to indemnify him against such liability under this
Section.

    
      
         

      

      
        
        

        
          

        

      

      
         

      

    

    Section 13.  Certain Reductions in
Indemnity.  The Corporation's indemnification of any executive
shall be reduced by any amounts which such person may collect as
indemnification: (a) under any policy of insurance purchased and maintained on
his behalf by the Corporation, or (b) from any other corporation, partnership,
joint venture, trust or other enterprise for whom the executive has served at
the request of the Corporation.

     

    Section 14.  Notification to
Shareholders.  If any expenses or other amounts are paid by way
of indemnification other than by court order or action by the Shareholders or by
an insurance carrier pursuant to insurance maintained by the Corporation, the
Corporation shall, not later than the time of delivery to the shareholders of
written notice of the next annual meeting of shareholders, unless such meeting
is held within three (3) months from the date of such payment, and, in any
event, within fifteen (15) months from the date of such payment, deliver either
personally or by mail to each shareholder of record at the time entitled to vote
for the election of directors a statement specifying the persons paid, the
amounts paid, and the nature and status at the time of such payment of the
litigation or threatened litigation.

     

    Section 15.  Constituent
Corporations.  For the purposes of this Section, references to
the "Corporation" shall include, in addition to any resulting corporation, any
constituent corporation (including any constituent of a constituent) absorbed in
a consolidation or merger, so that any executive of such a constituent
corporation shall stand in the same position under the provisions of this
Section with respect to the resulting or surviving corporation as he would if
its separate existence had contained.

     

    Section 16.  Savings
Clause.  If this Section or any portion hereof shall be
invalidated on any ground by any court of competent jurisdiction, then the
Corporation shall nevertheless indemnify each executive as to liability with
respect to any proceeding, whether internal or external, including a grand jury
proceeding or an action or suit brought by or in the right of the Corporation,
to the full extent permitted by any applicable portion of this Section that
shall not have been invalidated, or by any applicable provision of Florida
law.

     

    Section 17.  Effective
Date.  The provisions of this Section shall be applicable to
all proceedings commenced after the adoption hereof, whether arising from acts
or omissions occurring before or after its adoption.

     

    ARTICLE
IX.  AMENDMENT

     

    These Bylaws may be repealed or
amended, and new Bylaws may be adopted, by either the Board of Directors or the
Shareholders, but the Board of Directors may not amend or repeal any Bylaw
adopted by Shareholders if the Shareholders specifically provide that such Bylaw
is not subject to amendment or repeal by the Directors.

    
      
         

      

      
        
        

        
          

        

      

      
         

      

    

    
      EXHIBIT
B

    

    
      Bylaws
of Guarantor

    

    [see
attached]

    
      
         

      

      
        
        

        
          

        

      

      
         

      

    

    AMENDED
AND RESTATED BYLAWS OF

    

    NEOGENOMICS,
INC.,

    

    a Nevada
Corporation,

    

    As
Amended and Restated March __, 2009

    

    ARTICLE
I

    

    STOCKHOLDERS'
MEETINGS

    

    Section
1.1  Place of Meetings.

    

    All
meetings of the stockholders of NeoGenomics, Inc. (the “Corporation”) shall
be held at the Corporation's corporate headquarters, or at any other place,
within or without the State of Nevada, or by means of any electronic or other
medium of communication, as the Board of Directors of the Corporation (the
“Board”) may
designate for that purpose from time to time.

    

    Section
1.2  Annual Meetings.

    

    An annual
meeting of the stockholders shall be held each year on the date and at the time
set by the Board, at which time the stockholders shall elect, by the greatest
number of affirmative votes cast, the directors to be elected at the meeting and
transact such other business as properly may be brought before the
meeting.

    

    Section
1.3  Special Meetings.

    

    Special
meetings of the stockholders, for any purpose or purposes whatsoever, may be
called at any time by the Chairman of the Board, the Chief Executive Officer or
the Board.

    

    Section
1.4  Notice of Meetings.

    

    (a)  Notice
of each meeting of stockholders, whether annual or special, shall be given at
least ten (10) and not more than sixty (60) days prior to the date thereof by
the Secretary or any Assistant Secretary causing to be delivered to each
stockholder of record entitled to vote at such meeting a written notice stating
the time and place of the meeting and the purpose or purposes for which the
meeting is called. Such notice shall be signed by the Chief Executive Officer,
the Secretary or any Assistant Secretary and shall be (a) mailed postage prepaid
to a stockholder at the stockholder's address as it appears on the stock books
of the Corporation, or (b) delivered to a stockholder by any other method of
delivery permitted at such time by Nevada and federal law and by any exchange on
which the Corporation's shares shall be listed at such time.  If any
stockholder has failed to supply an address or  otherwise specify an
alternative method of delivery that is permitted by (b) above, notice shall be
deemed to have been given if mailed to the address of the Corporation's
corporate headquarters or published at least once in a newspaper having general
circulation in the county in which the Corporation's corporate headquarters is
located.

    
      
         

      

      
        
        

        
          

        

      

      
         

      

    

    

    (b)  It
shall not be necessary to give any notice of the adjournment of any meeting, or
the business to be transacted at an adjourned meeting, other than by
announcement at the meeting at which such adjournment is taken; provided,
however, that when a meeting is adjourned for 30 days or more, notice of the
adjourned meeting shall be given as in the case of the original
meeting.  The Corporation may transact any business which may have
been transacted at the original meeting.

    

    Section
1.5  Consent by Stockholders.

    

    Any
action, except the removal of directors, that the stockholders could take at a
meeting may be taken without a meeting if one or more written consents, setting
forth the action taken, shall be signed and dated, before or after such action,
by the holders of outstanding stock of each voting group entitled to vote
thereon having not less than the minimum number of votes with respect to each
voting group that would be necessary to authorize or take such action at a
meeting at which all voting groups and shares entitled to vote thereon were
present and voted.  The consent shall be delivered to the Corporation for
inclusion in the minutes or filing with the corporate records.
 

    

    Section
1.6  Quorum.

    

    (a)  The
presence in person or by proxy of the persons entitled to vote a majority of the
Corporation's voting shares at any meeting constitutes a quorum for the
transaction of business. Shares shall not be counted in determining the number
of shares represented or required for a quorum or in any vote at a meeting if
the voting of them at the meeting has been enjoined or for any reason they
cannot be lawfully voted at the meeting.

    

    (b)  The
stockholders present at a duly called or held meeting at which a quorum is
present may continue to do business until adjournment, notwithstanding the
withdrawal of stockholders leaving less than a quorum.

    

    (c)  In
the absence of a quorum, a majority of the shares present in person or by proxy
and entitled to vote may adjourn any meeting from time to time until a quorum
shall be present in person or by proxy.

    
      
         

      

      
        2

        
          

        

      

      
         

      

    

    Section
1.7  Voting Rights.

    

    (a)  Except
as otherwise provided in the Corporation’s Articles of Incorporation (as the
same has been or may be amended from time to time, the "Articles"), at each
meeting of the stockholders, each stockholder of record of the Corporation shall
be entitled to one vote for each share of stock standing in the stockholder's
name on the books of the Corporation. Except as otherwise provided by law, the
Articles or these Bylaws, if a quorum is present:  (i) directors shall
be elected by a plurality of the votes of the shares of capital stock of the
Corporation present in person or represented by proxy at the meeting and
entitled to vote on the election of directors; and (ii) action on any matter,
other than the election of directors, shall be approved if the majority of votes
cast in person or by proxy are in favor of such action.

    

    (b)  The
Board may fix a date as the record date for the purpose of determining
stockholders entitled to notice of or to vote at any meeting of stockholders.
 Such record date shall not precede the date on which the Board adopted the
resolution fixing the record date and shall not be more than sixty (60) days or
less than ten (10) days prior to the date of such meeting.

    

    Section
1.8  Proxies.

    

    Every
stockholder entitled to vote may do so either in person or by written,
electronic, telephonic or other proxy executed in accordance with the provisions
of Section 78.355 of the Nevada Revised Statutes.

    

    Section
1.9  Manner of Conducting Meetings.

    

    To the
extent not in conflict with Nevada law, the Articles or these Bylaws, meetings
of stockholders shall be conducted pursuant to such rules as may be adopted by
the chairman of such meeting.

    

    Section
1.10.  Nature of Business at Meetings of Stockholders.

    

    (a) No
business may be transacted at any special meeting of stockholders, other than
business that is (a) specified in the notice of meeting (or any supplement
thereto) given by or at the direction of the Board (or any duly authorized
committee thereof), or the Chief Executive Officer or Chairman of the Board or
(b) otherwise properly brought before the meeting by or at the direction of the
Board (or any duly authorized committee thereof), the Chairman of the Board, or
the Chief Executive Officer.

    

    (b) No
business may be transacted at any annual meeting of stockholders, other than
business that is (a) specified in the notice of meeting (or any supplement
thereto) given by or at the direction of the Board (or any duly authorized
committee thereof), (b) otherwise properly brought before the meeting by or at
the direction of the Board (or any duly authorized committee thereof), the
Chairman of the Board, or the Chief Executive Officer, or (c) otherwise properly
brought before the annual meeting by any stockholder of the Corporation (i) who
is a stockholder of record on the date of the giving of the notice provided for
in this Section 1.10 and on the record date for the determination of
stockholders entitled to vote at such annual meeting and (ii) who complies with
the notice procedures set forth in this Section 1.10.

    

    (c)  In
addition to any other applicable requirements, for business to be properly
brought by a stockholder before an annual meeting, such stockholder must have
given timely notice thereof in proper written form to the Secretary of the
Corporation.

    
      
         

      

      
        3

        
          

        

      

      
         

      

    

    

    (d)  To
be timely, a stockholder's notice to the Secretary must be delivered to or
mailed and received at the Corporation's corporate headquarters not less than
ninety (90) days nor more than one hundred twenty (120) days prior to the
anniversary date of the immediately preceding annual meeting of stockholders;
provided, however, that in the event that the annual meeting is called for a
date that is not within thirty (30) days before or after such anniversary date,
notice by the stockholder in order to be timely must be so received not later
than the close of business on the tenth (10th) day
following the day on which notice of the date of the annual meeting was mailed
or public disclosure of the date of the annual meeting was made, whichever first
occurs.

    

    (e)  To
be in proper written form, a stockholder's notice to the Secretary must set
forth as to each matter such stockholder proposes to bring before the annual
meeting of stockholders (a) a brief description of the business desired to be
brought before the meeting and the reasons for conducting such business at the
meeting, (b) the name and record address of such stockholder, (c) the class or
series and number of shares of capital stock of the Corporation which are owned
beneficially or of record by such stockholder, (d) a description of all
arrangements or understandings between such stockholder and any other person or
persons (including their names) in connection with the proposal of such business
by such stockholder and any material interest of such stockholder in such
business and (e) a representation that such stockholder intends to appear in
person or by proxy at the meeting to bring such business before the
meeting. 

    

    (f)  No
business shall be conducted at the annual meeting, or at any special meeting, of
stockholders except business brought before the meeting in accordance with the
procedures set forth in this Section 1.10. If the chairman of any meeting
determines that business was not properly brought before the meeting in
accordance with the foregoing procedures, the chairman shall declare to the
meeting that the business was not properly brought before the meeting and such
business shall not be transacted.

    

    ARTICLE
II

    DIRECTORS—MANAGEMENT

    

    Section
2.1  Powers.

    

    Subject
to the limitations of Nevada law, the Articles and these Bylaws as to action to
be authorized or approved by the stockholders, all corporate powers shall be
exercised by or under authority of, and the business and affairs of this
Corporation shall be controlled by, the Board.

    

    Section
2.2  Number and Qualification; Change in Number

    

    (a)  Subject
to Section 2.2(b), the authorized number of directors of this Corporation shall
be not less than two nor more than eight (8) , with the exact number to be
established from time to time by resolution of the Board. All directors of this
Corporation shall be at least twenty-one (21) years of age.

    
      
         

      

      
        4

        
          

        

      

      
         

      

    

    

    (b)  The
Board or the stockholders may increase the number of directors at any time and
from time to time; provided, however, that neither the Board nor the
stockholders may ever increase the number of directors by more than one during
any twelve (12) month period, except upon the affirmative vote of two-thirds
(2/3) of the directors, or the affirmative vote of the holders of two-thirds
(2/3) of all outstanding shares voting together and not by class. This provision
may not be amended except by a like vote.

    

    Section
2.3  Election.

    

    Each
director's term of office shall begin immediately after election and shall
continue until the next annual stockholders meeting and his successor is duly
elected and qualified.  Directors elected by the Board or stockholders
to fill a vacancy on the Board shall hold office for the balance of the term to
which such director is elected.

    

    Section
2.4.  Vacancies.

    

    (a)  Any
vacancies in the Board may be filled by a majority vote of the remaining
directors, though less than a quorum, or by a sole remaining director. Each
director so elected shall hold office for the balance of the term to which such
director is elected. The power to fill vacancies may not be delegated to any
committee appointed in accordance with these Bylaws.

    

    (b)  The
stockholders may at any time elect a director to fill any vacancy not filled by
the directors and may elect the additional director(s) at the meeting at which
an amendment of the Bylaws is voted authorizing an increase in the number of
directors.

    

    (c)  A
vacancy or vacancies shall be deemed to exist in case of the death, permanent
and total disability, resignation, retirement or removal of any director, if the
directors or stockholders increase the authorized number of directors but fail
to elect the additional director or directors at a meeting at which such
increase is authorized or at an adjournment thereof, or if the stockholders fail
at any time to elect the full number of authorized directors.

    

    (d)  If
the Board accepts the resignation of a director tendered to take effect at a
future time, the Board or the stockholders shall have power to immediately elect
a successor who shall take office when the resignation shall become
effective.

    

    (e)  No
reduction of the number of directors shall have the effect of removing any
director prior to the expiration of such director's term of office.

    

    Section
2.5  Removal of Directors.

    

    Any one
or more director(s) may be removed from office, with or without cause, by the
affirmative vote of two-thirds of all the outstanding shares voting together and
not by class.

    
      
         

      

      
        5

        
          

        

      

      
         

      

    

    

    Section
2.6  Resignations.

    

    Any
director of the Corporation may resign at any time either by oral tender of
resignation at any meeting of the Board or by giving written notice thereof to
the Chairman of the Board, Secretary or the Chief Executive Officer. Such
resignation shall take effect at the time it specifies, and the acceptance of
such resignation shall not be necessary to make it effective.

    

    Section
2.7  Place of Meetings.

    

    (a)  Regular
and special meetings of the Board shall be held at the corporate headquarters of
the Corporation or at such other place within or without the State of Nevada as
may be designated for that purpose by the Board.

    

    (b)  Meetings
of the Board may be held in person or by means of any electronic or other medium
of communication approved by the Board from time to time.

    

    Section
2.8  Chairman of the Board.  Except as otherwise provided in
these bylaws, the Chairman of the Board shall preside at all meetings of the
Board of Directors.  The Chairman of the Board may, but need not be an
employee of the Corporation.

    

    Section
2.9  Regular Meetings.

    

    (a)  Regular
meetings of the Board shall be held at such time and place within or without the
State of Nevada as may be agreed upon from time to time by a majority of the
Board.

    

    (b)  Notwithstanding
the provisions of Section 2.11, no notice need be provided of regular meetings,
except that a written notice shall be given to each director of the resolution
establishing a regular meeting date or dates, which notice shall set forth the
date, time and place of the meeting(s). Except as otherwise provided in these
Bylaws or the notice of the meeting, any and all business may be transacted at
any regular meeting of the Board.

    

    Section
2.10  Special Meetings.

    

    Special
meetings of the Board shall be held whenever called by the Chairman of the
Board, the Chief Executive Officer or two-thirds (2/3) of the directors. Except
as otherwise provided in these Bylaws or the notice of the meeting, any and all
business may be transacted at any special meeting of the
Board.

    
      
         

      

      
        6

        
          

        

      

      
         

      

    

    Section
2.11  Notice; Waiver of Notice.

    

    Notice of
each regular Board meeting not previously approved by the Board and each special
Board meeting shall be (a) mailed by U.S. mail to each director not later than
two (2) days before the day on which the meeting is to be held, (b) sent to each
director by overnight delivery service, telex, facsimile transmission, telegram,
cablegram, radiogram, e-mail, any other electronic transmission permitted by
Nevada law or delivered personally not later than 5:00 p.m. (EST time) on the
day before the date of the meeting, or (c) provided to each director by
telephone not later than 5:00 p.m. (EST time) on the day before the date of the
meeting. Any director who attends a regular or special Board meeting and (x)
waives notice by a writing filed with the Secretary, (y) is present thereat and
asks that his/her oral consent to the notice be entered into the minutes or (z)
takes part in the deliberations thereat without expressly objecting to the
notice thereof in writing or by asking that his/her objection be entered into
the minutes shall be deemed to have waived notice of the meeting and neither
that director nor any other person shall be entitled to challenge the validity
of such meeting.

    

    Section
2.12  Notice of Adjournment.

    

    Notice of
the time and place of holding an adjourned meeting need not be given to absent
directors if the time and place is fixed at the meeting adjourned.

    

    Section
2.13  Quorum.

    

    A
majority of the number of directors as fixed by the Articles or these Bylaws, or
by the Board pursuant to the Articles or these Bylaws, shall be necessary to
constitute a quorum for the transaction of business, and the action of a
majority of the directors present at any meeting at which there is a quorum,
when duly assembled, is valid as a corporate act; provided, however, that a
minority of the directors, in the absence of a quorum, may adjourn from time to
time or fill vacant directorships in accordance with Section 2.4 but may not
transact any other business. The directors present at a duly called or held
meeting at which a quorum is present may continue to do business until
adjournment, notwithstanding the withdrawal of directors, leaving less than a
quorum.

    

    Section
2.14  Action by Unanimous Written Consent.

    

    Any
action required or permitted to be taken at any meeting of the Board may be
taken without a meeting if all members of the Board consent in writing thereto.
Such written consent shall be filed with the minutes of the proceedings of the
Board and shall have the same force and effect as a unanimous vote of such
directors.

    

    Section
2.15  Compensation.

    

    The Board
may pay to directors a fixed sum for attendance at each meeting of the Board or
of a standing or special committee, a stated retainer for services as a
director, a stated fee for serving as a chair of a standing or special committee
and such other compensation, including benefits, as the Board or any standing
committee thereof shall determine from time to time. Additionally, the directors
may be paid their expenses of attendance at each meeting of the Board or of a
standing or special committee.

    
      
         

      

      
        7

        
          

        

      

      
         

      

    

    

    Section
2.16  Transactions Involving Interests of Directors.

    

    In the
absence of fraud, no contract or other transaction of the Corporation shall be
affected or invalidated by the fact that any of the directors of the Corporation
is interested in any way in, or connected with any other party to, such contract
or transaction or is a party to such contract or transaction; provided, however,
that such contract or transaction satisfies Section 78.140 of the Nevada Revised
Statutes. Each and every person who is or may become a director of the
Corporation hereby is relieved, to the extent permitted by law, from any
liability that might otherwise exist from contracting in good faith with the
Corporation for the benefit of such person or any person in which such person
may be interested in any way or with which such person may be connected in any
way. Any director of the Corporation may vote and act upon any matter, contract
or transaction between the Corporation and any other person without regard to
the fact that such director also is a stockholder, director or officer of, or
has any interest in, such other person; provided, however, that such director
shall disclose any such relationship and/or interest to the Board prior to a
vote and/or action.

    

    ARTICLE
III

    OFFICERS

    

    Section
3.1  Executive Officers.

    

    The
Corporation shall have a President, Secretary and a Treasurer.  The
officers of the Corporation may also include, without limitation, one or more of
each of the following: Chief Executive Officer, Chief Financial Officer,
Executive Chairman, Vice Chairman, Chief Corporate Officer, Chief Operating
Officer, Chief Medical Officer, Senior Executive Vice President, Executive Vice
President, Senior Vice President, Vice President, Group and/or Division
President. Any person may hold two or more offices. Each officer of the
Corporation shall be elected by the Board, may be classified by the Board as an
executive officer or a non-executive officer (or as a non-officer) at any time,
and shall serve at the pleasure of the Board.

    

    Section
3.2  Intentionally Omitted

    

    Section
3.3  Removal and Resignation; No Right to Continued
Employment

    

    (a)  Any
executive officer may be removed at any time by the Board, either with or
without cause.

    

    (b)  Any
officer may resign at any time by giving written notice to the Board, the Chief
Executive Officer or the Secretary of the Corporation. Any such resignation
shall take effect as of the date of the receipt of such notice, or at any later
time specified therein; provided, however, that such officer may be removed at
any time notwithstanding such resignation. Unless otherwise specified therein,
the acceptance of such resignation shall not be necessary to make it
effective.

    
      
         

      

      
        8

        
          

        

      

      
         

      

    

    

    (c)  The
fact that an employee has been elected by the Board to serve as an executive
officer or appointed to serve as an officer shall not entitle such employee to
remain an officer or employee of the Corporation.

    

    Section
3.4  Vacancies.

    

    A vacancy
in any office due to death, permanent and total disability, retirement,
resignation, removal, disqualification or any other cause may be filled in any
manner prescribed in these Bylaws for regular elections or appointments to such
office or may not be filled.

    

    Section
3.5  Executive Chairman and Vice Chairman.

    

    The
Executive Chairman shall preside, in the absence of the Chief Executive Officer,
at all meetings of the stockholders and shall exercise and perform such other
powers and duties as from time to time may be assigned by the Board. In the
absence of the Executive Chairman and the Chief Executive Officer, a Vice
Chairman shall preside at all meetings of the stockholders and exercise and
perform such other powers and duties as from time to time may be assigned by the
Board. A Vice Chairman need not be a member of the Board.

    

    Section
3.6  Chief Executive Officer.

    

    Subject
to the oversight of the Board, the Chief Executive Officer shall have general
supervision, direction and control of the business and affairs of the
Corporation. The Chief Executive Officer shall preside at all meetings of the
stockholders and, in the absence of the Chairman of the Board, at all meetings
of the Board. If not a member of the Board, the Chief Executive Officer shall be
an ex officio member of the Executive Committee of the Board and shall have the
general powers and duties of management usually vested in the office of chief
executive officer of a corporation and such other powers and duties as may be
assigned by the Board.

    

    Section
3.7    President.

    

    In the
absence or disability of the Chief Executive Officer, the
President  shall perform all of the duties of the Chief Executive
Officer and when so  acting shall have all the powers and be subject
to all the restrictions upon the Chief Executive Officer, including the power to
sign all instruments and to take all actions which the Chief Executive Officer
is authorized to perform by the  Board of Directors or these Bylaws.
The President shall have the general powers  and duties usually vested
in the office of president of a corporation and such  other powers and
duties as may be prescribed by the Board.

    
      
         

      

      
        9

        
          

        

      

      
         

      

    

    

    Section
3.8  Chief Financial Officer

    

    The Chief
Financial Officer shall exercise direction and control of the financial affairs
of the Corporation, including the preparation of the Corporation's financial
statements. The Chief Financial Officer shall have the general powers and duties
usually vested in the office of the chief financial officer of a corporation and
such other powers and duties as may be assigned by the Board.

    

    Section
3.9  Chief Operating Officer.

    

    Subject
to the oversight of the Chief Executive Officer, the Chief Operating Officer
shall exercise direction and control over the day-to-day operations of the
Corporation. In the case of the death or total and permanent disability of the
Chief Executive Officer and the President(s), the Chief Operating Officer or
Chief Corporate Officer, in order of rank or seniority, shall perform all of the
duties of such officer, and when so acting shall have all the powers of and be
subject to all the restrictions upon such officer, including the power to sign
all instruments and to take all actions that such officer is authorized to
perform by the Board or these Bylaws. The Chief Operating Officer shall have the
general powers and duties of management usually vested in the office of the
chief operating officer of a corporation and such other powers and duties as
from time to time may be assigned to the Chief Operating Officer by the
Executive Chairman, the Chief Executive Officer or Board.

    

    Section
3.10  Chief Corporate Officer.

    

    Subject
to the oversight of the Chief Executive Officer, the Chief Corporate Officer
shall exercise direction and control over the day-to-day corporate functions of
the Corporation. In the case of the death or total and permanent disability of
the Chief Executive Officer and the President, the Chief Operating Officer or
Chief Corporate Officer, in order of rank or seniority, shall perform all of the
duties of such officer, and when so acting shall have all the powers of and be
subject to all the restrictions upon such officer, including the power to sign
all instruments and to take all actions that such officer is authorized to
perform by the Board or these Bylaws. The Chief Corporate Officer shall have the
general powers and duties of management usually vested in the office of chief
corporate officer of a corporation and such other powers and duties as from time
to time may be assigned to the Chief Corporate Officer by the Executive
Chairman, the Chief Executive Officer or the Board.

    
      
         

      

      
        10

        
          

        

      

      
         

      

    

    

    Section
3.11 Chief Medical Officer

    

    The Chief
Medical Officer shall exercise direction and control of the medical affairs of
the Corporation, including the preparation of any medical related regulatory
documents and advising on any medical related matters for the
Corporation.  The Chief Medical Officer shall have the general powers
and duties usually vested in the office of the chief medical officer of a
corporation and such other powers and duties as may be assigned by the Executive
Chairman, the Chief Executive Officer or the Board.

    

    Section
3.12  Senior Executive Vice President, Executive Vice President,
Senior Vice President and Vice President.

    

    In the
case of the death or total and permanent disability of the Chief Executive
Officer and the President, the Chief Operating Officer and the Chief Corporate
Officer, a corporate Senior Executive Vice President, an Executive Vice
President, a Group President, in the order of rank and seniority, shall perform
all of the duties of such officer, and when so acting shall have all the powers
of and be subject to all the restrictions upon such officer, including the power
to sign all instruments and to take all actions that such officer is authorized
to perform by the Board or these Bylaws. Each such officer shall have the
general powers and duties usually vested in such office. Each operating region,
division, group or corporate staff function officer shall have the general
powers and duties usually vested in such office. Each such officer shall have
such other powers and perform such other duties as from time to time may be
assigned to them respectively by the Executive Chairman, the Chief Executive
Officer or the Board.

    

    Section
3.13  Secretary and Assistant Secretaries.

    

    (a)  The
Secretary shall  record and keep, or cause to be kept, all votes and
the minutes of all proceedings in a book or books to be kept for that purpose at
the corporate headquarters of the Corporation, or at such other place as the
Board may from time to time determine; and perform like duties for the Executive
and other committees of the Board, when required. In addition, the Secretary
shall keep or cause to be kept, at the registered office of the Corporation in
the State of Nevada, those documents required to be kept thereat by Section 5.2
of the Bylaws and Section 78.105 of the Nevada Revised Statutes.

    

    (b)  The
Secretary shall give, or cause to be given, notice of meetings of the
stockholders and special meetings of the Board, and shall perform such other
duties as may be assigned by the Executive Chairman, the Chief Executive Officer
or Board, under whose supervision the Secretary shall be. The Secretary shall
keep in safe custody the seal of the Corporation and affix the same to any
instrument requiring it. When required, the seal shall be attested by the
Secretary's; the Treasurer's or an Assistant Secretary's signature. The
Secretary or an Assistant Secretary hereby is authorized to issue certificates,
to which the corporate seal may be affixed, attesting to the incumbency of
officers of this Corporation or to actions duly taken by the Board, the
Executive Committee, any other committee of the Board or the
stockholders.

    
      
         

      

      
        11

        
          

        

      

      
         

      

    

    

    (c)  The
Assistant Secretary or Secretaries, in the order of their seniority, shall
perform the duties and exercise the powers of the Secretary and perform such
duties as the Executive Chairman, the Chief Executive Officer or Board of
Directors shall prescribe in the case of death or total and permanent disability
of the Secretary.

    

    Section
3.14  Treasurer and Assistant Treasurers.

    

    (a)  The
Treasurer shall deposit all moneys and other valuables in the name, and to the
credit, of the Corporation, with such depositories as may be determined by the
Treasurer. The Treasurer shall disburse the funds of the Corporation as may be
ordered by the Board or permitted by the Chief Executive Officer or Chief
Financial Officer, shall render to the Chief Executive Officer, Chief Financial
Officer and directors, whenever they request it, an account of all transactions
and shall have such other powers and perform such other duties as may be
prescribed by the Board or these Bylaws or by the Executive Chairman or the
Chief Executive Officer.

    

    (b)  The
Assistant Treasurer or Treasurers, in the order of their seniority, shall
perform the duties and exercise the powers of the Treasurer and perform such
duties as the Executive Chairman, the Chief Executive Officer or Board of
Directors shall prescribe in the case of death or total and permanent disability
of the Treasurer.

    

    Section
3.15  Additional Powers, Seniority and Substitution of
Officers.

    

    In
addition to the foregoing powers and duties specifically prescribed for the
respective officers, the Board may by resolution from time to time (a) impose or
confer upon any of the officers such additional duties and powers as the Board
may see fit, (b) determine the order of seniority among the officers, and/or (c)
except as otherwise provided above, provide that in the case of death or total
and permanent disability of any officer or officers, any other officer or
officers shall temporarily or indefinitely assume the duties, powers and
authority of the officer or officers who died or became totally and permanently
disabled. Any such resolution may be final, subject only to further action by
the Board, granting to any of the Chief Executive Officer, President, Executive
Chairman or Vice Chairman (or Chairmen) such discretion as the Board deems
appropriate to impose or confer additional duties and powers, to determine the
order of seniority among officers and/or to provide for substitution of officers
as above described.

    

    Section
3.16  Compensation.

    

    The
officers of the Corporation shall receive such compensation as shall be fixed
from time to time by the Board or a committee thereof. Unless otherwise
determined by the Board, no officer shall be prohibited from receiving any
compensation by reason of the fact that such officer also is a director of the
Corporation.

    
      
         

      

      
        12

        
          

        

      

      
         

      

    

    

    Section
3.17  Transaction Involving Interest of an Officer.

    

    In the
absence of fraud, no contract or other transaction of the Corporation shall be
affected or invalidated by the fact that any of the officers of the Corporation
is interested in any way in, or connected with any other party to, such contract
or transaction, or are themselves parties to such contract or transaction;
provided, however, that such contract or transaction complies with Section
78.140 of the Nevada Revised Statutes. Each and every person who is or may
become an officer of the Corporation hereby is relieved, to the extent permitted
by law, when acting in good faith, from any liability that might otherwise exist
from contracting with the Corporation for the benefit of such person or any
person in which such person may be interested in any way or with which such
person may be connected in any way.

    

    ARTICLE
IV

    EXECUTIVE
AND OTHER COMMITTEES

    

    Section
4.1  Standing Committees.

    

    (a)  The
Board may appoint an Executive Committee, an Audit Committee and a Compensation
Committee, consisting of such number of members as the Board may designate,
consistent with the Articles, these Bylaws and the laws of the State of
Nevada.

    

    (b)  The
Executive Committee shall have and may exercise, when the Board is not in
session, all of the powers of the Board in the management of the business and
affairs of the Corporation, but the Executive Committee shall not have the power
to fill vacancies on the Board, to change the membership of or to fill vacancies
in the Executive Committee or any other Committee of the Board, to adopt, amend
or repeal these Bylaws or to declare dividends or other
distributions.

    

    (c)  The
Audit Committee shall select and engage, on behalf of the Corporation and
subject to the consent of the stockholders, and fix the compensation of, a firm
of certified public accountants. It shall be the duty of the firm of certified
public accountants, which firm shall report to the Audit Committee, to audit the
books and accounts of the Corporation and its consolidated subsidiaries. The
Audit Committee shall confer with the auditors to determine, and from time to
time shall report to the Board upon, the scope of the auditing of the books and
accounts of the Corporation and its consolidated subsidiaries.  If
required by Nevada or federal laws, rules or regulations, or by the rules or
regulations of any exchange on which the Corporation's shares shall be listed,
the Board shall approve a charter for the Audit Committee and the Audit
Committee shall comply with such charter in the performance of its
duties.

    
      
         

      

      
        13

        
          

        

      

      
         

      

    

    

    (d)  The
Compensation Committee shall establish a general compensation policy for the
Corporation's directors and elected officers and shall have responsibility for
approving the compensation of the Corporation's directors, elected officers and
any other senior officers determined by the Compensation Committee. The
Compensation Committee shall have all of the powers of administration granted to
the Compensation Committee under the Corporation's non-qualified employee
benefit plans, including any stock incentive plans, long-term incentive plans,
bonus plans, retirement plans, deferred compensation plans, stock purchase plans
and medical, dental and insurance plans. In connection therewith, the
Compensation Committee shall determine, subject to the provisions of such plans,
the directors, officers and employees of the Corporation eligible to participate
in any of the plans, the extent of such participation and the terms and
conditions under which benefits may be vested, received or
exercised.  The Compensation Committee may delegate any or all of its
powers of administration under any or all of the Corporation's non-qualified
employee benefit plans to any committee or entity appointed by the Compensation
Committee. If required by any Nevada or federal laws, rules or regulations, or
by the rules or regulations of any exchange on which the Corporation's shares
shall be listed, the Board shall approve a charter for the Compensation
Committee and the Compensation Committee shall comply with such charter in the
performance of its duties.

    

    Section
4.2  Other Committees.

    

    Subject
to the limitations of the Articles, these Bylaws and the laws of the State of
Nevada, or duties not delegable by the Board, any or all of the responsibilities
and powers of the Board may be exercised, and the business and affairs of this
Corporation may be exercised or controlled by or under the authority of such
other committee or committees as may be appointed by the Board, including,
without limitation, a Nominating Committee, an Ethics, Quality and Compliance
Committee and a Corporate Governance Committee. The responsibilities and/or
powers to be exercised by any such committee shall be designated by the
Board.

    

    Section
4.3  Procedures.

    

    Meetings
and actions of committees shall be governed by, and held in accordance with, the
following provisions of Article II of these Bylaws: Section 2.9 (Regular
Meetings), Section 2.10 (Special Meetings), Section 2.11 (Notice; Waiver of
Notice), Section 2.12 (Notice of Adjournment), Section 2.13 (Quorum) and Section
2.14 (Action by Unanimous Written Consent), with such changes in the context of
these Bylaws as are necessary to substitute the committee and its members for
the Board and its members; provided, however, that the time of regular meetings
of committees may be determined either by resolution of the Board or by
resolution of the committee, that special meetings of committees may also be
called by resolution of the Board.  The Board may adopt rules for the
governance of any committee not inconsistent with the provisions of these
Bylaws. 

    

    ARTICLE
V

    CORPORATE
RECORDS AND REPORTS—INSPECTION

     

    Section
5.1  Records.

    

    The
Corporation shall maintain adequate and correct accounts, books and records of
its business and properties. All of such books, records and accounts shall be
kept at its corporate headquarters and/or at other locations within or without
the State of Nevada as may be designated by the Board.

    
      
        
        

         

      

      
        14

        
          

        

      

      
         

      

    

    

    Section
5.2  Articles, Bylaws and Stock Ledger.

    

    The
Corporation shall maintain and keep the following documents at its registered
office in the State of Nevada: (a) a certified copy of the Articles and all
amendments thereto; (b) a certified copy of these Bylaws and all amendments
thereto; and (c) the Stock Ledger (unless such Stock Ledger is kept by a third
party transfer agent).

    

    Section
5.3  Inspection.

    

        Stockholders
of the Corporation may inspect books and records of the Corporation in
accordance with Sections 78.105 and 78.257 of the Nevada Revised
Statutes.

    

    Section
5.4  Checks, Drafts, Etc.

    

    All
checks, drafts, or other orders for payment of money, notes or other evidences
of indebtedness, issued in the name of, or payable to, the Corporation, shall be
signed or endorsed only by such person or persons, and only in such manner, as
shall be authorized from time to time by the Board, the Chief Executive Officer,
the President, the Chief Financial Officer or the Treasurer.

    

    ARTICLE
VI

    OTHER
AUTHORIZATIONS

    

    Section
6.1  Execution of Contracts.

    

    Except as
otherwise provided in these Bylaws, the Board may authorize any officer or agent
of the corporation to enter into and execute any contract, document, agreement
or instrument in the name of and on behalf of the Corporation. Such authority
may be general or confined to specific instances. Unless so authorized by the
Board, no officer, agent or employee shall have any power or authority, except
in the ordinary course of business, to bind the Corporation by any contract or
engagement, to pledge its credit or to render it liable for any purpose or in
any amount.

    

    Section
6.2  Dividends or Other Distributions

    

    From time
to time, the Board may declare, and the Corporation may pay, dividends or other
distributions on its outstanding shares in the manner and on the terms and
conditions provided by the laws of the State of Nevada and the Articles, subject
to any contractual restrictions to which the Corporation is then
subject.

    
      
         

      

      
        15

        
          

        

      

      
         

      

    

    

    ARTICLE
VII

    SHARES
AND TRANSFER OF SHARES

    

    Section
7.1  Shares.

    

    (a)  The
shares of the capital stock of the Corporation may be represented by
certificates or uncertificated. Each registered holder of shares of capital
stock, upon written request to the Secretary of the Corporation, shall be
provided with a stock certificate representing the number of shares owned by
such holder.

    

    (b)  Certificates
for shares shall be in such form as the Board may designate and shall be
numbered and registered as they are issued. Each shall state the name of the
record holder of the shares represented thereby; its number and date of
issuance; the number of shares for which it is issued; the par value; a
statement of the rights, privileges, preferences and restrictions, if any; a
statement as to rights of redemption or conversion, if any; and a statement of
liens or restrictions upon transfer or voting, if any, or, alternatively, a
statement that certificates specifying such matters may be obtained from the
Secretary of the Corporation.

    

    (c)  Every
certificate for shares must be signed by the Chief Executive Officer or the
President and the Secretary or an Assistant Secretary, or must be authenticated
by facsimiles of the signatures of the Chief Executive Officer or the President
and the Secretary or an Assistant Secretary. Before it becomes effective, every
certificate for shares authenticated by a facsimile or a signature must be
countersigned by a transfer agent or transfer clerk, and must be registered by
an incorporated bank or trust company, either domestic or foreign, as registrar
of transfers.

    

    (d)  Even
though an officer who signed, or whose facsimile signature has been written,
printed, or stamped on a certificate for shares ceases, by death, resignation,
retirement or otherwise, to be an officer of the Corporation before the
certificate is delivered by the Corporation, the certificate shall be as valid
as though signed by a duly elected, qualified and authorized officer if it is
countersigned by the signature or facsimile signature of a transfer clerk or
transfer agent and registered by an incorporated bank or trust company, as
registrar of transfers.

    

    (e)  Even
though a person whose facsimile signature as, or on behalf of, the transfer
agent or transfer clerk has been written, printed or stamped on a certificate
for shares ceases, by death, resignation, or otherwise, to be a person
authorized to so sign such certificate before the certificate is delivered by
the Corporation, the certificate shall be deemed countersigned by the facsimile
signature of a transfer agent or transfer clerk for purposes of meeting the
requirements of this section.

    
      
         

      

      
        16

        
          

        

      

      
         

      

    

    

    Section
7.2  Transfer on the Books.

    

    Upon
surrender to the Secretary or transfer agent of the Corporation of a certificate
for shares duly endorsed or accompanied by proper evidence of succession,
assignment or authority to transfer, it shall be the duty of the Corporation or
its transfer agent to issue a new certificate, if requested by the transferee,
to the person entitled thereto, cancel the old certificate and record the
transaction upon its books.

    

    Section
7.3  Lost or Destroyed Certificates.

    

    The Board
may direct, or may authorize the Secretary to direct, a new certificate or
certificates to be issued in place of any certificate or certificates
theretofore issued by the Corporation alleged to have been lost or destroyed,
upon the Secretary's receipt of an affidavit of that fact by the person
requesting the replacement certificate for shares so lost or destroyed. When
authorizing such issue of a new certificate or certificates, the Board or
Secretary may, in its or the Secretary's discretion, and as a condition
precedent to the issuance thereof, require the owner of such lost or destroyed
certificate or certificates, or such owner's legal representative, to advertise
the same in such manner as it shall require and/or give the Corporation a bond
in such sum as it may direct as indemnity against any claim that may be made
against the Corporation with respect to the certificate alleged to have been
lost or destroyed.

    

    Section
7.4  Transfer Agents and Registrars.

    

    The
Board, the Chief Executive Officer, the Chief Financial Officer or the Secretary
may appoint one or more transfer agents or transfer clerks, and one or more
registrars, who may be the same person, and may be the Secretary of the
Corporation, an incorporated bank or trust company or any other person or
entity, either domestic or foreign.

    

    Section
7.5  Fixing Record Date for Dividends, Etc.

    

    The Board
may fix a time, not exceeding fifty (50) days preceding the date fixed for the
payment of any dividend or distribution, or for the allotment of rights, or when
any change or conversion or exchange of shares shall go into effect, as a record
date for the determination of the stockholders entitled to receive any such
dividend or distribution, or any such allotment of rights, or to exercise the
rights in respect to any such change, conversion, or exchange of shares, and, in
such case, only stockholders of record on the date so fixed shall be entitled to
receive such dividend, distribution, or allotment of rights, or to exercise such
rights, as the case may be, notwithstanding any transfer of any shares on the
books of the Corporation after any record date fixed as aforesaid.

    

    Section
7.6  Record Ownership.

    

    The
Corporation shall be entitled to recognize the exclusive right of a person
registered as such on the books of the Corporation as the owner of shares of the
Corporation's stock to receive dividends or other distributions and to vote as
such owner, and shall not be bound to recognize any equitable or other claim to
or interest in such shares on the part of any other person, whether or not the
Corporation shall have express or other notice thereof, except as otherwise
provided by law.

    
      
         

      

      
        17

        
          

        

      

      
         

      

    

    

    ARTICLE
VIII

    AMENDMENTS
TO BYLAWS

    

    Section
8.1  By Stockholders.

    

    New or
restated bylaws may be adopted, or these Bylaws may be repealed, amended and/or
restated, at any meeting of the stockholders, by the affirmative vote of the
holders of a majority of all outstanding shares voting together and not by
class, except amendment of Section 2.5 shall require the approval of two-thirds
(2/3) of all outstanding shares voting together (unless the Certificate of
Designation of any preferred stock of the Corporation requires the affirmative
vote of such holders of preferred stock).

    

    Section
8.2  By Directors.

    

    Subject
to the right of the stockholders to adopt, amend and/or restate or repeal these
Bylaws, as provided in Section 8.1, the Board may adopt, amend, or repeal any of
these Bylaws, except amendment of Section 2.5 shall require the approval of
two-thirds (2/3) of all outstanding shares voting together (unless the
Certificate of Designation of any preferred stock of the Corporation requires
the affirmative vote of such holders of preferred stock) by the affirmative vote
of two-thirds of the directors.  This power may not be delegated to
any committee appointed in accordance with these Bylaws.

    

    Section
8.3  Record of Amendments.

    

    Whenever
an amendment or a new Bylaw is adopted, it shall be copied in the book of
minutes with the original Bylaws, in the appropriate place. If any Bylaw is
repealed, the fact of repeal, with the date of the meeting at which the repeal
was enacted, or written assent was filed, shall be stated in said
book.

    
      
         

      

      
        18

        
          

        

      

      
         

      

    

    

    ARTICLE
IX

    INDEMNIFICATION
OF DIRECTORS AND OFFICERS

    

    Section
9.1  Indemnification in Actions, Suits or Proceedings other than those
by or in the Right of the Corporation.

    

    Any
person who was or is a party or is threatened to be made a party to any
threatened, pending or completed action, suit or proceeding, whether civil,
criminal, administrative or investigative (except an action by or in the right
of the Corporation) (a "Proceeding"), by
reason of the fact that such person is or was a director, officer, employee or
agent of the Corporation, or is or was serving at the request of the Corporation
as a director, officer, employee or agent of another corporation, partnership,
joint venture, trust or other enterprise, shall be indemnified and held harmless
by the Corporation to the fullest extent permitted by Nevada law against
expenses, including attorneys' fees, judgments, fines and amounts paid in
settlement actually and reasonably incurred by such person in connection with
such Proceeding (collectively, "Costs"). The
termination of any Proceeding by judgment, order, settlement, conviction, or
upon a plea of nolo contendere or its equivalent, shall not, of itself, create a
presumption that the person did not act in good faith and in a manner which such
person reasonably believed to be in or not opposed to the best interests of the
Corporation, and that, with respect to any criminal action or proceeding, such
person had reasonable cause to believe that such person's conduct was
unlawful.

    

    Section
9.2   Indemnification in Actions, Suits or Proceedings by or in
the Right of the Corporation.

    

    The
Corporation shall indemnify any person who was or is a party or is threatened to
be made a party to any threatened, pending or completed Proceeding by or in the
right of the Corporation to procure a judgment in its favor by reason of the
fact that such person is or was a director, officer, employee or agent of the
Corporation, or is or was serving at the request of the Corporation as a
director, officer, employee, or agent of another corporation, partnership, joint
venture, trust or other enterprise against Costs incurred by such person in
connection with the defense or settlement of such action or
suit.  Indemnification may not be made for any claim, issue or matter
as to which such person has been adjudged by a court of competent jurisdiction,
after exhaustion of all appeals therefrom, to be liable to the Corporation or
for amounts paid in settlement to the Corporation, unless and only to the extent
that the court in which the action or suit was brought or other court of
competent jurisdiction determines upon application that in view of all the
circumstances of the case, the person is fairly and reasonably entitled to
indemnity for such expenses as the court deems proper.

    

    Section
9.3  Indemnification by a Court.

    

    If a
claim under Sections 9.1 or 9.2 is not paid in full by the Corporation within 30
days after a written claim has been received by the Corporation, the claimant
may at any time thereafter bring suit against the Corporation to recover the
unpaid amount of the claim and, if successful in whole or in part, the claimant
shall be entitled to be paid also the expense of prosecuting such claim. It
shall be a defense to any such action (other than an action brought to enforce a
claim for Costs incurred in defending any Proceeding in advance of its final
disposition where the required undertaking, if any is required, has been
tendered to the Corporation) that the claimant has failed to meet a standard of
conduct which makes it permissible under Nevada law for the Corporation to
indemnify the claimant for the amount claimed. Neither the failure of the
Corporation (including the Board, independent legal counsel, or the
stockholders) to have made a determination prior to the commencement of such
action that indemnification of the claimant is permissible in the circumstances
because such claimant has met such standard of conduct, nor an actual
determination by the Corporation (including the Board, independent legal
counsel, or the stockholders) that the claimant has not met such standard of
conduct, shall be a defense to the action or create a presumption that the
claimant has failed to meet such standard of conduct.

    
      
         

      

      
        19

        
          

        

      

      
         

      

    

    

    Section
9.4  Expenses Payable in Advance.

    

    The
Corporation shall pay the Costs incurred by any person entitled to
indemnification in defending a Proceeding as such Costs are incurred and in
advance of the final disposition of a Proceeding; provided, however, that the
Corporation shall pay the Costs of such person only upon receipt of an
undertaking by or on behalf of such person to repay the amount if it is
ultimately determined by a court of competent jurisdiction that such person is
not entitled to be indemnified by the Corporation.

    

    Section
9.5  Nonexclusivity of Indemnification and Advancement of
Expenses.

    

    The right
to indemnification and advancement of Costs authorized in this Article IX or
ordered by a court: (a) does not exclude any other rights to which a person
seeking indemnification or advancement of expenses may be entitled under the
Articles of the Corporation or any agreement, vote of stockholders or
disinterested directors or otherwise, for either an action in such person's
official capacity or an action in another capacity while holding such person's
office, except that indemnification, unless ordered by a court pursuant to
Nevada law or the advancement of expenses made pursuant to Section 9.4, may not
be made to or on behalf of any director or officer if a final adjudication
establishes that such person's acts or omissions involved intentional
misconduct, fraud or a knowing violation of the law and was material to the
cause of action; and (b) continues for a person who has ceased to be a director,
officer, employee, or agent and inures to the benefit of the heirs, executors
and administrators of such a person.

    

    Section
9.6  Insurance.

    

    The
Corporation may purchase and maintain insurance or make other financial
arrangements on behalf of any person who is or was a director, officer, employee
or agent of the Corporation, or is or was serving at the request of the
Corporation as a director, officer, employee or agent of another corporation,
partnership, joint venture, trust or other enterprise in accordance with Section
78.752 of the Nevada Revised Statutes.

    

    Section
9.7  Certain Definitions.

    

    (a)  For
purposes of this Article IX, references to "the Corporation" shall include, in
addition to the resulting corporation, any constituent corporation (including
any constituent of a constituent) absorbed in a consolidation or merger which,
if its separate existence had continued, would have had power and authority to
indemnify its directors, officers, employees or agents so that any person who is
or was a director, officer, employee or agent of such constituent corporation or
is or was serving at the request of such constituent corporation as a director,
officer, employee or agent of another corporation, partnership, joint venture,
trust, employee benefit plan or other enterprise, shall stand in the same
position under the provisions of this Article IX with respect to the resulting
or surviving corporation as such person would have with respect to such
constituent corporation if its separate existence had
continued.

    
      
         

      

      
        20

        
          

        

      

      
         

      

    

    

    (b)  For
purposes of this Article IX, references to "fines" shall include any excise
taxes assessed on a person with respect to an employee benefit
plan.

    

    (c)  For
purposes of this Article IX, references to "serving at the request of the
Corporation" shall include any service as a director, officer, employee or agent
of the Corporation which imposes duties on, or involves services by, such
director, officer, employee or agent with respect to an employee benefit plan,
its participants or beneficiaries;

    

    (d)  For
purposes of this Article IX, a person who acted in good faith and in a manner
such person reasonably believed to be in the interest of the participants and
beneficiaries of an employee benefit plan shall be deemed to have acted in a
manner "not opposed to the best interests of the Corporation" as referred to in
this Article IX.

    

    (e)  For
purposes of this Article IX, the term "Board" shall mean the Board of the
Corporation or, to the extent permitted by the laws of Nevada, as the same exist
or may hereafter be amended, its Executive Committee. On vote of the Board, the
Corporation may assent to the adoption of Article IX by any subsidiary, whether
or not wholly owned.

    

    Section
9.8  Indemnification of Witnesses.

    

    To the
extent that any director, officer, employee, or agent of the Corporation is by
reason of such position, or a position held with another entity at the request
of the Corporation, a witness in any action, suit or proceeding, such person
shall be indemnified against all Costs actually and reasonably incurred by such
person or on such person's behalf in connection therewith.

    

    Section
9.9  Indemnification Agreements.

    

    The
Corporation may enter into agreements with any director, officer, employee, or
agent of the Corporation providing for indemnification to the full extent
permitted by Nevada law.

    

    Section
9.10  Actions Prior to Adoption of Article IX.

    

    The
rights provided by this Article IX shall be available whether or not the claim
asserted against the director, officer, employee, or agent is based on matters
which antedate the adoption of this Article IX.

    

    Section
9.11  Severability.

    

    If any
provision Article IX shall for any reason be determined to be invalid, the
remaining provisions hereof shall not be affected thereby but shall remain in
full force and effect.

    
      
         

      

      
        21

        
          

        

      

      
         

      

    

    

    ARTICLE
X

    CORPORATE
SEAL

    

    The
corporate seal shall be circular in form and shall have inscribed thereon the
name of the Corporation, the date of its incorporation and the word
"Nevada".

    

    ARTICLE
XI

    INTERPRETATION

    

    Reference
in these Bylaws to any provision of Nevada law or the Nevada Revised Statutes
shall be deemed to include all amendments thereto and the effect of the
construction and determination of validity thereof by the Nevada Supreme
Court.

    
      
         

      

      
        22

        
          

        

      

      
         

      

    

    
      EXHIBIT
C

    

    
      Schedules

    

    [see
attached]

    
      
         

      

      
        
        

        
          

        

      

      
         

      

    

    EXHIBIT
C

     

    AMENDED AND RESTATED
SCHEDULES

     

    
      	
              Schedule
      1.2

            	
              Accounts
      Payable Over 120 Days That Are Permitted
  Indebtedness:

            

    

     

    Aspen
Capital Advisors not to exceed $65,000

    K&L
Gates, LLP not to exceed $500,000

    Path Labs
of Fort Myers not to exceed $80,000

    HCSS, LLC
dba Bridge Labs not to exceed $40,000

    

    
      	
              Schedule
      2.3

            	
              Borrower’s
      Operating Account for Disbursements

            

    

     

    [***]

    

    
      	
              Schedule
      5.3B

            	
              Third-Party
      Contracts With Payor’s Representing at Least 5% of Cash
      Receipts

            

    

     

    Medicare

    United
Healthcare

    

    
      	
              Schedule
      7.3

            	
              Subsidiaries
      of NeoGenomics, Inc., a Nevada Corporation (Holding
    Company)

            

    

     

    NeoGenomics
Laboratories, Inc., a Florida Corporation

     

    Subsidiaries
of NeoGenomics Laboratories, Inc., a Florida Corporation (Operating
Company)

     

    None

    

    Capitalization
of NeoGenomics, Inc, a Nevada Corporation

    

    
      
        
          
            	
                    Common
      Shares Authorized:

                  	 	 	100,000,000	 
	
                    Common
      Stock Outstanding (as of 3/31/09):

                  	 	 	33,056,021	 
	 
      	 	 	 	 
	
                    Preferred
      Stock Authorized:

                  	 	 	10,000,000	 
	
                    Preferred
      Stock Outstanding (as of 3/31/09):

                  	 	
                    None

                  	 
	 
      	 	 	 	 
	
                    Warrants
      Outstanding (as of 3/31/09):

                  	 	 	6,542,755	 
	
                    Options
      Outstanding (as of 12/31/08):

                  	 	 	3,724,422	 

          

        

      

    

    

    This
Schedule 7.3 dealing with the Capitalization of the Guarantor shall be deemed to
be automatically updated by any disclosures which appear in the Guarantor’s
public filings with the Securities and Exchange Commission.

    

    Capitalization
of NeoGenomics Laboratories, Inc, a Florida Corporation

    

    
      
        
          	
                  Common
      Shares Authorized:

                	 	 	100	 
	
                  Common
      Sock Outstanding:

                	 	 	100	 

        

      

    

    

    Board
of Directors of NeoGenomics, Inc, a Nevada Corporation

     

    
      
        
          	
                  Michael
      T. Dent, M.D.

                	
                  George
      G. O’Leary

                
	
                  Robert
      P. Gasparini

                	
                  Peter
      M. Peterson

                
	
                  Marvin
      E. Jaffe, M.D.

                	
                  William
      J. Robison

                
	
                  Steven
      C. Jones

                	
                  Douglas
      M. VanOort

                

        

         

      

    

    [***] Information redacted
pursuant to a confidential treatment request.  An unredacted version
of this Agreement has been filed separately with the Securities and Exchange
Commission.

     

    
      
         

      

      
        1

        
          

        

      

      
         

      

    

    

    Board
of Directors of NeoGenomics Laboratories, Inc, a Florida
Corporation

     

    Douglas
M. VanOort

    Michael
T. Dent, M.D.

    Robert P.
Gasparini

    

    
      	
              Schedule
      7.4A

            	
              Locations
      of Leased Properties

            

    

     

    12701
Commonwealth Drive, Suites 1-9

    Fort
Myers, FL 33913

    

    618
Grassmere Park Drive, Suite 20

    Nashville,
TN  37211

    

    6 Morgan
Street, Suite 150

    Irvine,
CA 92618

    

    9548
Topanga Canyon Blvd.

    Chatsworth,
CA  91311

    

    
      	
              Schedule
      7.4B

            	
              [***]

            

    

     

    
      
        
          
            	
                    Schedule
      7.5

                  	 
      	
                    Affiliate
      Contracts

                     

                    HCSS, LLC

                     

                    On
      March 11, 2005, NeoGenomics entered into an agreement with HCSS, LLC and
      eTelenext, Inc. to enable NeoGenomics to use eTelenext, Inc’s laboratory
      information system (LIS).  HCSS, LLC is a holding company
      created to build a small laboratory network for the 50 small commercial
      genetics laboratories in the United States.  HCSS, LLC is owned
      66.7% by Dr. Michael T. Dent, our Chairman.  By becoming the
      first customer of HCSS in the small laboratory network, the Company saved
      approximately $152,000 in up front licensing fees.  Under the
      terms of the agreement, the Company paid $22,500 over three months to
      customize this software and pays an annual membership fee of $6,000 per
      year and monthly transaction fees of between $2.50 - $10.00 per completed
      test, depending on the volume of tests performed.  As of
      December, 2007, the Company was incurring approximately $8,000 -
      $10,000/month in fees.  The eTelenext system is an elaborate LIS
      that is in use at many larger labs.  By utilizing the eTelenext
      system, the Company has vastly increased the productivity of its
      technologists.

                  
	 
      	 
      	 
      
	 
      	
                      

                  	
                    Certain Consulting Agreements with Board
      Members

                     

                    The
      Company has consulting arrangements with two members of its Board of
      Directors, Mr. Steven Jones and Mr. George O’Leary, to provide various
      consulting services.  Although there are no written agreements,
      per se, each of these arrangements has been approved by the Company’s
      Board of Directors.  Mr. Jones receives approximately $150/hour
      and is paid through Aspen Capital Advisors.  Mr. O’leary
      receives approximately $1,000/day and is paid through SKS
      Consulting.  The maximum amounts payable by the Company under
      the consulting agreements referenced in this paragraph will not exceed
      $500,000 per fiscal
year.

                  

          

        

      

    

     

    [***] Information redacted
pursuant to a confidential treatment request.  An unredacted version
of this Agreement has been filed separately with the Securities and Exchange
Commission.

     

    
      
         

      

      
        2

        
          

        

      

      
         

      

    

    

    
      
        
          	 
      	
                    

                	
                  Certain Leasing Arrangements with Gulf Pointe
      Capital, LLC

                   

                  On
      September 30, 2008, the Borrower entered into a Master Lease Agreement
      (the “Master Lease”) with Gulfpointe Capital, LLC which allows the
      Borrower to obtain operating lease capital from time to
      time.  Three members of the Guarantor’s Board of Directors
      Steven Jones, Peter Petersen and Marvin Jaffe, are affiliated with
      Gulfpointe Capital, LLC.  On September 30, 2008, the Borrower
      also entered into the first lease schedule under the Master Lease
      Agreement which provided for a sale leaseback on approximately $130,000 of
      used laboratory equipment (“Lease Schedule #1”).  This
      sale/leaseback transaction was entered into after it was determined that
      Leasing Technologies International Inc., the Borrower’s primary source of
      operating lease funds, was unable to consummate this transaction under
      their lease line with the Borrower.  Messrs Jones, Peterson and
      Jaffe recused themselves from all aspects of both sides of this
      transaction.  The lease has a 30 month term and a lease rate
      factor of 0.039683/month, which equates to monthly payments of $5,154.88
      during the term.  Gulfpointe Capital LLC (“Gulfpointe”) also
      received warrants to purchase 32,475 shares of the Guarantor’s common
      stock with an exercise price of $1.08/share and a five year
      term.  At the end of the term, the Borrower’s options are as
      follows:

                   

                  a.)   
      Purchase not less than all of the equipment for its then fair market value
      not to exceed 15% of the original equipment cost.

                  b.)   
      Extend the lease term for a minimum of six months.

                  c.)   
      Return not less than all the equipment at the conclusion of the lease
      term.

                   

                  On
      February 9, 2009, the Borrower entered into a second schedule under the
      Master Lease for the sale leaseback and purchase of approximately $118,000
      of used laboratory equipment (“Lease Schedule #2”). This sale/leaseback
      transaction was entered into after it was determined that Leasing
      Technologies International Inc., the Borrower’s primary source of
      operating lease funds, was unable to consummate this transaction under
      their lease line with the Borrower.  Messrs. Jones, Peterson and
      Jaffe recused themselves from all aspects of both sides of this
      transaction.  The lease has a 30 month term at the same lease
      rate factor per month as Lease Schedule #1, which equates to monthly
      payments of $4,690.41 during the term.  As part of Lease
      Schedule #2, on February 9, 2009, the Guarantor and Gulfpointe terminated
      their original warrant agreement, dated September 30, 2008, and replaced
      it with a new warrant to purchase 83,333 shares of the Guarantor’s common
      stock.  Such new warrant has a five year term and an exercise
      price of $0.75/share.  The Borrower’s options at the end of the
      term of Lease Schedule #2 are the same as for Lease Schedule
      #1.

                   

                  Certain Stock and Warrant Agreements with Douglas
      M. VanOort

                   

                  On March 16, 2009, the Guarantor
      entered into a subscription agreement with the Douglas M. VanOort Living
      Trust for the purchase of 625,000 shares of common stock at a purchase
      price of $0.80/share, which resulted in gross proceeds to the Guarantor of
      $500,000.  Also on March 16, 2009, the Guarantor entered into a
      warrant agreement with Douglas M. VanOort granting him the rights to
      purchase 625,000 shares of common stock at a purchase price of
      $1.05/share.  Such warrant has a five year term and is subject
      to certain vesting requirements specified in the
  warrant.

                

        

      

    

     

    
      
         

      

      
        3

        
          

        

      

      
         

      

    

    

    
      
        
          	
                  Schedule
      7.6

                	
                    

                	
                  Litigation

                   

                  US Labs

                   

                  On October 26, 2006, US Labs
      filed a complaint in the Superior Court of the State of California for the
      County of Los Angeles (entitled Accupath Diagnostics Laboratories, Inc. v.
      NeoGenomics, Inc., et al., Case No. BC 360985) (the “Lawsuit”) against the
      Company and Robert Gasparini, as an individual, and certain other
      employees and non-employees of NeoGenomics (the “Defendants”) with respect
      to claims arising from discussions with current and former employees of US
      Labs.  On March 18, 2008, we reached a preliminary agreement to
      settle US Labs’ claims, and in accordance with SFAS No. 5, Accounting For
      Contingencies, as of December 31, 2007 we accrued a $375,000 loss
      contingency, which consisted of $250,000 to provide for the Company’s
      expected share of this settlement, and $125,000 to provide for the
      Company’s share of the estimated legal fees.

                   

                  On April 23, 2008, the Company
      and US Labs entered into the Settlement Agreement; whereby, both parties
      agreed to settle and resolve all claims asserted in and arising out of the
      aforementioned lawsuit. Pursuant to the Settlement Agreement, the
      Defendants are required to pay $500,000 to US Labs, of which $250,000 was
      paid on May 1, 2008 with funds from the Company’s insurance carrier and
      the remaining $250,000 will be paid by the Company on the last day of each
      month in equal installments of $31,250 commencing on May 31,
      2008.  Under the terms of the Settlement Agreement, there are
      certain provisions agreed to in the event of default.  As of
      March 31, 2009, there were no remaining payments due under the Settlement
      Agreement.

                   

                  FCCI Commercial Insurance
      Company

                   

                  A
      civil lawsuit is currently pending between the Company and its liability
      insurer, FCCI Commercial Insurance Company ("FCCI") in the 20th Judicial
      Circuit Court in and for Lee County, Florida (Case No.
      07-CA-017150).  FCCI filed the suit on December 12, 2007 in
      response to the Company's demands for insurance benefits with respect to
      an underlying action involving US Labs (a settlement agreement has since
      been reached in the underlying action, and thus that case has now
      concluded).  Specifically, the Company maintains that the
      underlying plaintiff's allegations triggered the subject insurance
      policy's personal and advertising injury coverage.  In the
      lawsuit, FCCI seeks a court judgment that it owes no obligation to the
      Company regarding the underlying action (FCCI does not seek monetary
      damages).  The Company has counterclaimed against FCCI for
      breach of the subject insurance policy, and seeks recovery of defense
      costs incurred in the underlying matter, amounts paid in settlement
      thereof, and fees and expenses incurred in litigating with
      FCCI.  The court recently denied a motion by FCCI for judgment
      on the pleadings, and the parties are proceeding with
      discovery.  We intend to aggressively pursue all remedies in
      this matter and believe that the courts will ultimately find that FCCI had
      a duty to provide coverage in the US Labs
  litigation.

                

        

      

    

    
      
         

      

      
        4

        
          

        

      

      
         

      

    

    

    
      
        
          	 
      	
                    

                	
                  Dr. Peter Kohn

                   

                  In
      October 2004, Dr. Peter Kohn resigned as Lab Director of NeoGenomics. His
      employment contract with the Company ended September 30, 2004 and was not
      renewed. There was communication between Mr. Thomas White, former CEO and
      Dr. Kohn in October regarding health coverage and unused vacation time. In
      November 2004, the company received correspondence from Terry and Frazier,
      LLP, Dr. Kohn’s attorney relating to health care coverage, unused vacation
      time and business expenses related to November 2004. Mr. White responded
      that the Company would use the unpaid vacation time to cover Dr. Kohn’s
      health insurance until the issue is resolved and that the business
      expenses fell outside the contract terms and therefore would not be
      reimbursed. Dr. Kohn’s contract stipulated that this agreement superseded
      all prior agreements and therefore prior claims related to prior
      agreements were resolved with the signing of the most recent agreement.
      The Company believes that it has a strong documented case relating to its
      position regarding Dr. Kohn’s claims which would hold up in any court
      proceeding.  However, in the event that the Company is found to
      be liable for some or all of Dr. Kohn’s claims, the amounts in question
      would not be material to the ongoing operations of the
      Company.  The Company booked accrued severance expense of
      $12,352 to cover Dr. Kohn’s unused vacation pay up to the date of his
      termination and paid approximately $400/month to cover his health
      insurance against this accrual until June of 2007 when the Company was
      notified that Dr. Kohn had gotten insurance elsewhere.

                   

                  On January 12, 2005, the Company
      received a complaint filed in the Circuit Court for Seminole County,
      Florida by its former Laboratory Director, Dr. Peter Kohn.  The
      complaint alleged that the Company owed Dr. Kohn approximately $22,000 in
      back vacation pay and other unspecified damages.  The Company
      believes that it owes Dr. Kohn no more than approximately $12,352, of
      which it has already paid substantially all of this by virtue of the
      Company continuing to pay Dr. Kohn’s health insurance
      premiums.

                   

                  On
      March 5, 2007, the Company received an amended complaint filed in the
      Circuit Court for Seminole County, Florida by Dr. Kohn.  The
      complaint alleges the following (a) that Dr. Kohn is owed $12,600 for 22
      unused vacation days and 4 unused sick days resulting from his first
      contract from Oct 2002 to Sept 2003; (b) that Dr. Kohn is owed $14,054 for
      25 unused vacation days and four unused sick days (at a rate of
      $484.64/day), (c) that Dr. Kohn is owed $10,664 for thirty days of notice
      time from Oct 7, 2004 to Nov 5, 2004 and $917 for rent reimbursement and
      $442 for meal and auto expense, and (d) that Dr. Kohn is entitled to
      recoup legal fees.

                   

                  The
      Company believes that all of Dr. Kohn’s claims related to the first
      contract (see (a) above) are unenforceable since the second contract
      clearly stated that it superseded all prior claims.  With
      respect to Dr. Kohn’s claims in paragraph (b) above, the Company has
      acknowledged that it owed Dr. Kohn $12,352 as of the date of termination
      for 25 days of unused vacation time and has been using this money to pay
      his insurance premiums.  The Company further believes that Dr.
      Kohn’s claims from (c) above are without merit, since the contract had
      already lapsed on Sept 30, 2004 and the Company received an email message
      from Dr. Kohn saying that he had resigned.  Thus, either of the
      above reasons would have obviated the need for 30 days
      notice.   Similarly, the Company does not believe that Dr.
      Kohn is entitled to attorneys fees.

                   

                  In
      March 2007, the Company filed a motion to dismiss most of the third
      amended complaint, except for the count dealing with the unused vacation
      pay from the second contract (count b above), which the Company has
      acknowledged that it owed to Dr. Kohn.  On May 1, 2007, the
      judged dismissed two of the four counts that the Company had requested be
      dismissed.  On June 13, 2007, the Company filed its answer to
      Dr. Kohn’s remaining claims and the both sides are currently engaged in
      discovery.  There has been no meaningful activity on this case
      since the summer of 2007, and no trial has been set for the remaining
      matters.  Should Dr. Kohn continue to pursue this action, the
      Company intends to vigorously pursue its defense of this matter, and even
      if the Company were found liable for Dr. Kohn’s claims, the Company does
      not believe the amounts in question would be material to the ongoing
      operations of the
Company.

                

        

      

    

    
      
         

      

      
        5

        
          

        

      

      
         

      

    

    

    
      
        
          
            	 
      	 
      	
                    Thomas Schofield

                     

                    On January 16, 2009, the Borrower
      initiated litigation against Thomas Schofield, who had served as the
      Borrower’s Director of Operations from June 2005 until his resignation in
      late December 2008.  The suit, which was filed in the Circuit
      Court for the Twentieth Judicial District in and for Lee County Florida
      (the “Court”), sought the enforcement of Mr. Schofield’s Confidentiality,
      Non-Solicitation and Non-Competition Agreement.  An emergency
      trial was held on January 28, 2009 in Fort Myers, FL.  At such
      trial the judge affirmed in part and denied in part the Borrower’s request
      for a preliminary injunction against Mr. Schofield and his new employer,
      Laboratory Corporation of America (Lab Corp.).  On April 2,
      2009, the Court issued a written ruling with the specific
      injunction.  The injunction enjoins Mr. Schofield from working
      in any management capacity other than as Director of  Logistics
      for Lab Corp within 1,000 miles of the Borrower’s main headquarter
      facility in Fort Myers.  The order also enjoins Mr. Schofield
      from soliciting any of the Borrowers customers either individually or in
      concert with Lab Corp.

                     

                    Other Litigation in the Normal Course of
      Business

                     

                    The Credit Parties are also
      subject to legal proceedings, claims and litigation arising in the
      ordinary course of business where (a) the amount in controversy does not
      exceed $50,000 and (b) no injuctive relief is being sought by the
      parties.  We do not expect the ultimate costs to resolve these
      matters to have a material adverse effect on our consolidated financial
      position, results of operations or cash flows.

                  
	 	 	 
	
                    Schedule
      7.11

                  	 
      	
                    Intellectual
      Property

                     

                    The
      Company has received a registered trademark for the name “NeoGenomics” for
      use in the business in which it currently operates and related
      businesses.

                  
	 	 	 
	
                    Schedule
      7.15A

                  	 
      	
                    Existing
      Indebtedness, Investments, Guarantees and Certain
  Contracts

                  
	 
      	 
      	 
      
	 
      	 
      	
                    Existing
      Indebtedness of Guarantor

                  
	 
      	 
      	 
      
	 
      	 
      	
                    None

                  
	 
      	 
      	 
      
	 
      	
                      

                  	
                    Existing
      Indebtedness and Contracts for Indebtedness by
  Borrower

                  

          

        

      

    

     

    
      
         

      

      
        6

        
          

        

      

      
         

      

    

     

    
      
        
          
            	 
      	 	 
      	 	 
      	 	
                    Amount of

                  	 	
                    Start

                  	 	 	 	
                    Term

                  	 	 	 
	 
      	 	
                    Lessor (Capitalized Leases)

                  	 	
                    Asset Description

                  	 	
                    lease

                  	 	
                    Date

                  	 	
                    Term

                  	 	
                    Date

                  	 	
                    Payment

                  	 
	 
      	 	 
      	 	 
      	 	 	 	 
      	 	 	 	 
      	 	 	 
	
                    1

                  	 	
                    US Express Lease

                  	 	
                    Computer Equipment

                  	 	$	11,204	 	
                    Mar-07

                  	 	
                    36

                  	 	
                    Mar-10

                  	 	$	413	 
	
                    2

                  	 	
                    Balboa Capital

                  	 	
                    Furniture & fixtures

                  	 	 	19,820	 	
                    Apr-07

                  	 	
                    60

                  	 	
                    Mar-12

                  	 	 	441	 
	
                    3

                  	 	
                    VAR 222707 - PC Connections

                  	 	
                    Computer Equipment

                  	 	 	6,245	 	
                    Feb-07

                  	 	
                    36

                  	 	
                    Jan-10

                  	 	 	372	 
	
                    4

                  	 	
                    VAR res 13107 - PC Connection

                  	 	
                    Computer Equipment

                  	 	 	3,554	 	
                    Feb-07

                  	 	
                    36

                  	 	
                    Jan-10

                  	 	 	299	 
	
                    5

                  	 	
                    California Beckman

                  	 	
                    Cytomics PC 500

                  	 	 	136,118	 	
                    Mar-07

                  	 	
                    60

                  	 	
                    Feb-12

                  	 	 	2,792	 
	
                    6

                  	 	
                    Baytree

                  	 	
                    BMC Software/customer svc

                  	 	 	15,783	 	
                    Mar-07

                  	 	
                    36

                  	 	
                    Mar-10

                  	 	 	552	 
	
                    7

                  	 	
                    Royal bank of america

                  	 	
                    Abbott molecular Thermobrite

                  	 	 	80,936	 	
                    Feb-07

                  	 	
                    48

                  	 	
                    Jan-11

                  	 	 	2,289	 
	
                    8

                  	 	
                    Beckman Coulter Lease

                  	 	
                    Flow Cytometer

                  	 	 	125,064	 	
                    Apr-06

                  	 	
                    60

                  	 	
                    Mar-11

                  	 	 	2,691	 
	
                    9

                  	 	
                    Marlin Lease

                  	 	
                    Ikonisys comupter support equip

                  	 	 	48,230	 	
                    Sep-06

                  	 	
                    60

                  	 	
                    Aug-11

                  	 	 	1,201	 
	
                    10

                  	 	
                    B of A Lease

                  	 	
                    Computer hardware & servers

                  	 	 	98,405	 	
                    Sep-06

                  	 	
                    60

                  	 	
                    Aug-11

                  	 	 	2,366	 
	
                    11

                  	 	
                    AEL Lease

                  	 	
                    IkoniScope

                  	 	 	100,170	 	
                    Sep-06

                  	 	
                    60

                  	 	
                    Aug-11

                  	 	 	2,316	 
	
                    12

                  	 	
                    GE Capital Corp

                  	 	
                    IkoniScope

                  	 	 	100,170	 	
                    Sep-06

                  	 	
                    60

                  	 	
                    Aug-11

                  	 	 	2,105	 
	
                    13

                  	 	
                    Beckman Coulter

                  	 	
                    Coulter Hematology Analyzer

                  	 	 	18,375	 	
                    Nov-06

                  	 	
                    60

                  	 	
                    Oct-11

                  	 	 	761	 
	
                    14

                  	 	
                    Bank of America

                  	 	
                    Computer hardware & servers

                  	 	 	8,954	 	
                    Nov-06

                  	 	
                    60

                  	 	
                    Oct-11

                  	 	 	228	 
	
                    15

                  	 	
                    Royal Bank (BMT) 24K Lease

                  	 	
                    Computer hardware & servers

                  	 	 	23,494	 	
                    Dec-06

                  	 	
                    48

                  	 	
                    Nov-10

                  	 	 	718	 
	
                    16

                  	 	
                    Royal Bank (BMT) 18K Lease

                  	 	
                    Computer hardware & servers

                  	 	 	17,661	 	
                    Dec-06

                  	 	
                    48

                  	 	
                    Nov-10

                  	 	 	549	 
	
                    17

                  	 	
                    Toshiba Lease

                  	 	
                    Phone system

                  	 	 	42,784	 	
                    Jan-07

                  	 	
                    60

                  	 	
                    Dec-11

                  	 	 	998	 
	
                    18

                  	 	
                    Key Equipment

                  	 	
                    Genetic imaging system

                  	 	 	124,820	 	
                    Aug-07

                  	
                     

                  	
                    60

                  	 	
                    Jul-12

                  	 	 	3,090	 
	
                    19

                  	 	
                    Great America

                  	 	
                    Genetic imaging system

                  	 	 	55,920	 	
                    Aug-07

                  	 	
                    60

                  	 	
                    Jul-12

                  	 	 	1,392	 
	
                    20

                  	 	
                    Bank of America

                  	 	
                    Seacoast billing software

                  	 	 	74,788	 	
                    Sep-07

                  	 	
                    36

                  	 	
                    Aug-10

                  	 	 	3,125	 
	
                    21

                  	 	
                    Think Leasing/H&IT Capital

                  	 	
                    Ikoniscope, Great Plains s/w, etc

                  	 	 	292,993	 	
                    Jan-08

                  	 	
                    60

                  	 	
                    Jan-13

                  	 	 	6,534	 
	 
      	 	 
      	 	 
      	 	$	1,405,489	 	 
      	 	 	 	 
      	 	$	35,234	 

          

        

      

    

     

    
      
        	 
      	 
      	
                Investments
      Held by Guarantor

              
	 
      	 
      	 
      
	 
      	 
      	
                $200,000
      Convertible Note Receivable from Power3 Medical Products,
    Inc.

              
	 
      	 
      	 
      
	 
      	 
      	
                Investments
      Held by Subsidiary

              
	 
      	 
      	 
      
	 
      	 
      	
                None

              
	 
      	 
      	 
      
	
                Schedule
      7.15B

              	 
      	
                Indebtedness with a Maturity
      Date During the Term – See Schedule 7.15A

              
	 
      	 
      	 
      
	
                Schedule
      7.16

              	
                  

              	
                Other Agreements - See
      Schedule 7.5

              

      

    

    
      
         

      

      
        7

        
          

        

      

      
         

      

    

    

    
      	
              Schedule
      7.17

            	
              Insurance

            

    

    

    
      	
              Commercial Insurance Schedule

            
	 	 	 
      	 	 
      	 	 	 	 
      	 	
              Effective

            	 	
              Expiration

            	 	 
      
	
              Broker / Agent

            	 	
              Carrier (Ins. Co)

            	 	
              Type

            	 	
              Policy Number

            	 	
              Limit

            	 	
              Date

            	 	
              Date

            	 	
              Note:

            
	
              1

            	 	
              Gulfshore Insurance

            	 	
              Admiral
      Insurance Co.

            	 	
              Professional Liability

            	 	
              E000000559302

            	 	
              $1
      mil / $3 mil

            	 	
              10/9/2007

            	 	
              10/9/2008

            	 	
              All
      Locations

            
	
              2

            	 	
              Gulfshore Insurance

            	 	
              
                Travelers
      Indemnity Co. of CT

              

            	 	
              Workers' Comp

            	 	
              IACRUB-4649C88-4-07

            	 	
              EL-$500,000

            	 	
              5/4/2007

            	 	
              5/4/2008

            	 	
              All
      Locations

            
	
              3

            	 	N/A	 	
              Brickstreet Mutual
      Ins. Co

            	 	
              WV
      Workers Comp

            	 	
              WC10203816-01

            	 	
              EL-$500,000

            	 	
              2/19/2007

            	 	
              2/19/2008

            	 	
              WV
      Stae Ins. Co.

            
	
              4

            	 	
              Lott & Gaylor

            	 	
              FCCI
      - FL

            	 	
              Commercial Property

            	 	
              CP0003390-1

            	 	
              $1.7
      mil

            	 	
              4/15/2007

            	 	
              4/15/2008

            	 	
              FL
      only

            
	
              5

            	 	
              Lott & Gaylor

            	 	
              FCCI
      - FL

            	 	
              General Liability

            	 	
              GL00052821-1

            	 	
              $1
      mil / $2 mil

            	 	
              4/15/2007

            	 	
              4/15/2008

            	 	
              FL
      only

            
	
              6

            	 	
              Lott & Gaylor

            	 	
              FCCI
      - FL

            	 	
              Crime

            	 	
              CR0000676-1

            	 	
              $50,000

            	 	
              4/15/2007

            	 	
              4/15/2008

            	 	
              FL
      Admin only

            
	
              7

            	 	
              Lott & Gaylor

            	 	
              FCCI
      - TN

            	 	
              commercial Property

            	 	
              CPP0006352-2

            	 	
              $225,841

            	 	
              5/31/2007

            	 	
              5/31/2008

            	 	
              TN
      Only

            
	
              8

            	 	
              Lott & Gaylor

            	 	
              FCCI
      - TN

            	 	
              commercial liability

            	 	
              CPP0006352-2

            	 	
              $1
      mil / $2 mil

            	 	
              5/31/2007

            	 	
              5/31/2008

            	 	
              TN
      Only

            
	
              9

            	 	
              Gulfshore Insurance

            	 	
              Mount
      Vernon Ins.

            	 	
              commercial Property

            	 	
              CF2166377

            	 	
              $593,000

            	 	
              9/21/2007

            	 	
              9/21/2008

            	 	
              CA
      Only

            
	
              10

            	 	
              Gulfshore Insurance

            	 	
              Admiral
      Insurance Co.

            	 	
              commercial liability

            	 	
              CA00001186101

            	 	
              $1
      mil / $2 mil

            	 	
              9/21/2007

            	 	
              9/21/2008

            	 	
              CA
      Only

            
	
              11

            	 	
              Lott & Gaylor

            	 	
              FCCI
      - Ins. Co.

            	 	
              Umbrella

            	 	
              UMB0005093-1

            	 	
              excess
      of primary

            	 	
              4/15/2007

            	 	
              4/15/2008

            	 	
              FL/TN

            
	
              12

            	 	
              Gulfshore Insurance

            	 	
              Mt.
      Hawley Ins. Co.

            	 	
              Umbrella

            	 	
              MXL0365587

            	 	
              $3
      mil excess of underlying

            	 	
              8/10/2007

            	 	
              4/15/2008

            	 	
              All
      States

            
	
              13

            	 	
              Gulfshore Insurance

            	 	
              Travelers Indemnity
      Co.

            	 	
              Auto

            	 	
              BA4547L23A

            	 	
              $1,000,000

            	 	
              6/28/2007

            	 	
              6/28/2008

            	 	
              All
      States/Any Auto

            
	
              14

            	 	
              Lott & Gaylor

            	 	
              American
      Home Assurance Co.

            	 	
              Executive D&O

            	 	
              108-55-03

            	 	
              $2
      mil single limit

            	 	
              6/15/2007

            	 	
              6/15/2008

            	 	
              All
      States

            

    

    

    
      	
              Schedule
      7.18A

            	
              Borrower’s
      Names

            

    

     

    NeoGenomics
Laboratories, Inc.

    NeoGenomics
Laboratories

    

    
      	
              Schedule
      7.18B

            	
              Chief
      Executive Offices and Other Places of
Business

            

    

     

    Chief Executive
Offices

    12701
Commonwealth Drive, Suites 1-9

    Fort
Myers, FL 33913

    

    Other Places of
Business

    618
Grassmere Park Drive, Suite 20

    Nashville,
TN  37211

    

    6 Morgan
Street, Suite 150

    Irvine,
CA 92618

    

    9548
Topanga Canyon Blvd.

    Chatsworth,
CA  91311

    

    
      	
              Schedule
      8.8

            	
              Post-Closing
      Matters

            

    

     

    
      	
              Schedule
      9.2

            	
              Permitted
      Indebtedness

            

    

     

    All
Capital Leases listed in Schedule 7.15A

    
      
         

      

      
        8

        
          

        

      

      
         

      

    

    
      	
              Schedule
      9.3

            	
              Permitted
      Liens

            

    

     

    Purchase
Money on all Equipment financed through the Capital Leases listed on Schedule
7.15A

     

    
      	
              Schedule
      9.4

            	
              New
      Facilities

            

    

     

    [***]

    

    [***]
Information redacted pursuant to a confidential treatment request.  An
unredacted version of this Agreement has been filed separately with the
Securities and Exchange Commission.

    
      
         

      

      
        9

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00177-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00177-of-00352.parquet"}]]